Rituximab 利妥昔单抗

利妥昔单抗由百健和罗氏（包括美国的基因泰克，日本的中外制药）联合研发，于1997年11月26日获得美国食品药品管理局（FDA）批准，1998年6月2日获得欧洲药物管理局（EMA）批准，2001年6月20日获得日本医药品医疗器械综合机构（PMDA）批准，2008年4月21日被中国食品药品监督管理局（CFDA）批准上市，并由百健和罗氏在美国、欧洲、日本和中国市场销售，商品名为Rituxan® 和 MabThera®。

利妥昔单抗是一种靶向于CD20的人鼠嵌合型单克隆抗体，其与表达在B‑淋巴细胞表面的CD20抗原结合，通过补体依赖的细胞毒作用（CDC）和抗体依赖的细胞毒作用（ADCC）杀伤肿瘤B细胞。该药批准的适应症为非霍奇金淋巴瘤、慢性淋巴细胞白血病、类风湿性关节炎、肉芽肿血管炎和显微镜下多血管炎。

Rituxan® 和 MabThera®是静脉注射剂（溶液），每瓶含100 mg/10 mL或500 mg/50 mL利妥昔单抗。非霍奇金淋巴瘤的推荐剂量为375 mg/m2。慢性淋巴细胞白血病的推荐剂量是第1疗程（28天）375 mg/m2，第2-6疗程500 mg/m2，并与FC联合治疗。类风湿性关节炎需联合甲氨蝶呤共同治疗，推荐剂量为1000 mg/次，前后两次用药间隔2周，24周为一个疗程。肉芽肿血管炎和显微镜下多血管炎需联合糖皮质激素共同治疗，推荐剂量为375 mg/m2，每周一次，共4周。

目录：

基本信息

更新时间：2017-03-13

药品名称：
Rituximab 利妥昔单抗
研发代码：
IDEC-102; IDEC-C2B8; R-105; RG-105; RO-452294
商品名称：
Rituxan®  /  MabThera®  /  Ristova®  /  美罗华®
作用机制：
CD20-directed cytolytic effects ADCC and CDC effects
适应症：
非霍奇金淋巴瘤,慢性淋巴细胞白血病,类风湿性关节炎,肉芽肿性血管炎,显微镜下多血管炎
研发阶段：
批准上市
研发公司：
百健 (原研) 中外制药,基因泰克
年销售额：
$8608.5 Million (Y2015)
$8696.5 Million (Y2014);
$8600.1 Million (Y2013);
$8273.0 Million (Y2012);
$7743.8 Million (Y2011)
ATC号：
L01XC02
主要国家或地区批准情况

更新时间：2017-02-23

批准日期 NDA号 商品名 适应症 剂型 规格 公司 审查类别
1997-11-26 BLA 103705/BLA 103737 Rituxan 非霍奇金淋巴瘤, 慢性淋巴细胞白血病, 类风湿性关节炎 注射剂，溶液 100 mg/10 mL; 500 mg/50 mL 基因泰克,百健 Orphan
展示更多
批准日期 NDA号 商品名 适应症 剂型 规格 公司 审查类别
1998-06-02 EMEA/H/C/000165 MabThera 非霍奇金淋巴瘤, 慢性淋巴细胞白血病, 类风湿性关节炎, 肉芽肿性血管炎, 显微镜下多血管炎 注射剂，溶液，浓缩 100 mg/10 mL; 500 mg/50 mL 罗氏
1998-06-02 EMEA/H/C/000165 MabThera 非霍奇金淋巴瘤 注射剂，溶液 1400 mg/11.7 mL 罗氏
展示更多
批准日期 NDA号 商品名 适应症 剂型 规格 公司 审查类别
2001-06-20 21300AMY00273000 Rituxan 非霍奇金B细胞淋巴瘤, CD20阳性滤泡性淋巴瘤, 类风湿性关节炎 注射剂，溶液 100 mg/10 mL; 500 mg/50 mL 基因泰克 Orphan
展示更多
批准日期 NDA号 商品名 适应症 剂型 规格 公司 审查类别
2008-04-21 S20080044/S20080045 MabThera/美罗华 非霍奇金淋巴瘤, 慢性淋巴细胞白血病, 类风湿性关节炎, 肉芽肿性血管炎, 显微镜下多血管炎 注射剂，溶液 100 mg/10 mL; 500 mg/50 mL 罗氏
展示更多
生物信息

更新时间：2016-09-08

类型 完整抗体
种属 嵌合体
分子式 C6426H9900N1700O2008S44
分子量 144510
CAS号 174722-31-7
表达体系 中国仓鼠卵巢细胞（CHO）表达
Clinical Trial 信息
NCT号
试验标题
适应症
阶段
状态
NCT02727803
Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)
Leukemia/Lymphoma/Myeloma/Myel...MoreLeukemia/Lymphoma/Myeloma/Myeloproliferative Diseases
Recruiting
Phase Ⅱ
NCT02689986
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
Cold Agglutinin Disease/Autoim...MoreCold Agglutinin Disease/Autoimmune Hemolytic Anemia
Recruiting
Phase Ⅱ
NCT02692248
Evaluation of Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma N...MoreEvaluation of Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to Autologous Stem Cell Transplantation (ASCT)
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT02446457
Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT02670616
Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B...MoreStudy of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Epstein-Barr Virus-positive Di...MoreEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT02293109
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or...MoreCarfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
Contiguous Stage II Adult Lymp...MoreContiguous Stage II Adult Lymphoblastic Lymphoma/Noncontiguous Stage II Adult Lymphoblastic Lymphoma/Stage I Adult Lymphoblastic Lymphoma/Stage III Adult Lymphoblastic Lymphoma/Stage IV Adult Lymphoblastic Lymphoma/Untreated Adult Acute Lymphoblastic Leukemia
Recruiting
Phase Ⅰ
NCT02451111
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Follicular Lymphoma
Recruiting
Phase Ⅱ
NCT02682641
Evaluation of the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With In...MoreEvaluation of the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Mantle Cell Lymphoma
Recruiting
Phase Ⅱ
NCT02747043
Study to Access if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Lymphoma, Non-Hodgkin
Recruiting
Phase Ⅲ
NCT02329080
A Trial on a New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous...MoreA Trial on a New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT02337985
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphom...MoreGene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
AIDS-Related Burkitt Lymphoma/...MoreAIDS-Related Burkitt Lymphoma/AIDS-Related Diffuse Large B-cell Lymphoma/AIDS-Related Plasmablastic Lymphoma/AIDS-Related Primary Effusion Lymphoma/HIV Infection
Recruiting
N/A
NCT02735876
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subj...MoreA Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Withdrawn
Phase Ⅲ
NCT02303119
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
Follicular Lymphoma
Recruiting
Phase Ⅲ
NCT02405676
BNHL-2015 for Children or Adolescents in China
Mature B-cell Non-Hodgkin Lymp...MoreMature B-cell Non-Hodgkin Lymphoma
Recruiting
Phase Ⅱ/Ⅲ
NCT02626455
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin...MoreStudy of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Lymphoma, Non-Hodgkin
Recruiting
Phase Ⅲ
NCT02366663
Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem...MoreCombination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell...MoreRecurrent Diffuse Large B-Cell Lymphoma/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅲ
NCT02592876
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large ...MoreTreatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Lymphoma, B-cell/Lymphoma, Lar...MoreLymphoma, B-cell/Lymphoma, Large B-Cell, Diffuse/Lymphoma, Follicular, Grade 3b/Follicular Lymphoma, Grade 3b
Recruiting
Phase Ⅱ
NCT02391545
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untre...MoreA Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
CD20+ Follicular Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02731560
Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pa...MoreRituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT02371096
Comparative Pharmacokinetic Trial of RGB-03 and MabThera
Rheumatoid Arthritis
Not yet recruiting
Phase Ⅰ
NCT02339922
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia/F...MoreChronic Lymphocytic Leukemia/Follicular Lymphoma/Lymphoplasmacytic Lymphoma/Mantle Cell Lymphoma/Marginal Zone Lymphoma/Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue/Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue/Small Lymphocytic Lymphoma/Waldenstrom Macroglobulinemia
Recruiting
Phase Ⅱ
NCT02313389
Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma
Primary CNS Lymphoma.
Recruiting
Phase Ⅲ
NCT02371148
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Recruiting
Phase Ⅱ
NCT02538926
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asp...MoreEtoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
B Acute Lymphoblastic Leukemia...MoreB Acute Lymphoblastic Leukemia/B Lymphoblastic Lymphoma/Recurrent Adult Acute Lymphoblastic Leukemia/Recurrent B Lymphoblastic Lymphoma/Recurrent T Lymphoblastic Leukemia/Lymphoma/Refractory B Lymphoblastic Lymphoma/Refractory T Lymphoblastic Lymphoma/T Acute Lymphoblastic Leukemia/T Lymphoblastic Lymphoma
Not yet recruiting
Phase Ⅱ
NCT02594163
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse La...MoreStudy of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma ...MoreDiffuse Large B-cell Lymphoma Refractory/Follicular B-cell Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅱ
NCT02314403
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Kidney Failure, Chronic/Renal ...MoreKidney Failure, Chronic/Renal Insufficiency
Recruiting
Phase Ⅰ
NCT02530515
Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Pati...MoreTrial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)
Leukemia/Chronic Lymphocytic L...MoreLeukemia/Chronic Lymphocytic Leukemia
Recruiting
Phase Ⅱ
NCT02657447
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Non-Hodgkin Lymphoma
Not yet recruiting
Phase Ⅰ
NCT02417129
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Lymphoma, Non-Hodgkin
Completed
Phase Ⅲ
NCT02453087
A Study of Escalating Doses of DCDS0780A in Patients With Relapsed or Refractory B-cell Non-Hodgkin'...MoreA Study of Escalating Doses of DCDS0780A in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅰ
NCT02332941
Treatment -Resistant Neovascular Age-Related Macular Degeneration
Macular Degeneration
Completed
Phase Ⅰ
NCT02284984
Synergetic B-cell Immodulation in SLE
Lupus Erythematosus, Systemic
Recruiting
Phase Ⅱ
NCT02541565
Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse La...MorePembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Stage I Diffuse Large B-Cell L...MoreStage I Diffuse Large B-Cell Lymphoma/Stage II Diffuse Large B-Cell Lymphoma/Stage III Diffuse Large B-Cell Lymphoma/Stage IV Diffuse Large B-Cell Lymphoma
Recruiting
N/A
NCT02758925
CyBeR Association in Relapsed/Refractory DLBCL
Diffuse Large B Cell Lymphoma
Not yet recruiting
Phase Ⅱ
NCT02753062
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Recruiting
Phase Ⅱ
NCT02734771
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse ...MoreA Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma
Not yet recruiting
Phase Ⅱ
NCT02285062
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemot...MoreEfficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Lymphoma, Large B-Cell, Diffus...MoreLymphoma, Large B-Cell, Diffuse
Recruiting
Phase Ⅲ
NCT02468791
MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Recruiting
Phase Ⅲ
NCT02394119
Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic ...MoreOfatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome
Nephrotic Syndrome
Recruiting
Phase Ⅱ
NCT02315118
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
B-Cell Chronic Lymphocytic Leu...MoreB-Cell Chronic Lymphocytic Leukemia/Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02456207
A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphom...MoreA Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
B-cell Non Hodgkin's Lymphoma
Recruiting
Phase Ⅱ
NCT02576275
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With R...MoreA Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Indolent Non-Hodgkin's Lymphom...MoreIndolent Non-Hodgkin's Lymphoma/Follicular Lymphoma/Small Lymphocytic Lymphoma/Marginal Zone Lymphoma
Recruiting
Phase Ⅲ
NCT02423837
Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy W...MoreBendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
Follicular Lymphoma
Recruiting
Phase Ⅲ
NCT02792491
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Pati...MorePhase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Diffuse Large B-cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT02624492
To Determine the Maximum Tolerated Dose of BI 836826-GemOx and Then the Efficacy of BI 836826-GemOx ...MoreTo Determine the Maximum Tolerated Dose of BI 836826-GemOx and Then the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLCBL
Lymphoma, Large B-Cell, Diffus...MoreLymphoma, Large B-Cell, Diffuse
Recruiting
Phase Ⅱ
NCT02752204
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B...MoreAn Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT02436707
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT02419469
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic...MoreAugmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Leukemia/Precursor-B Acute Lym...MoreLeukemia/Precursor-B Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma/Lymphoma
Recruiting
Phase Ⅱ
NCT02427620
A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients ...MoreA Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT02400437
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobuli...MoreTrial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Recruiting
Phase Ⅱ
NCT02383589
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Pati...MoreA Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris
Pemphigus Vulgaris (PV)
Recruiting
Phase Ⅲ
NCT02628405
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Ce...MoreR-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma/...MoreDiffuse Large B-Cell Lymphoma/Recurrent Diffuse Large B-Cell Lymphoma/Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma/Refractory Diffuse Large B-Cell Lymphoma/Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma/Transformed Recurrent Non-Hodgkin Lymphoma
Not yet recruiting
Phase Ⅰ/Ⅱ
NCT02753647
Chidamide Plus R-CHOP in Elderly DLBCL
Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT02471911
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅰ
NCT02545959
Intrathecal Rituximab in Progressive Multiple Sclerosis
Multiple Sclerosis, Chronic Pr...MoreMultiple Sclerosis, Chronic Progressive/Nervous System Diseases
Recruiting
Phase Ⅱ
NCT02617485
MabionCD20® Compared to MabThera® in Lymphoma Patients
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅲ
NCT02807103
Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Eosinophilic Granulomatosis Wi...MoreEosinophilic Granulomatosis With Polyangiitis (EGPA)
Not yet recruiting
Phase Ⅲ
NCT02752815
Reduced Chemotherapy in Low Risk DLBCL
Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅳ
NCT02525172
Immune Modulation Therapy for Pompe Disease
Pompe Disease
Recruiting
Phase Ⅳ
NCT02772822
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, ...MoreA Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
Diffuse Large B Cell Lymphoma
Not yet recruiting
Phase Ⅲ
NCT02378298
Rituximab (RTX) Therapy in Patients With Active TAO
Ophthalmopathy, Thyroid-Associ...MoreOphthalmopathy, Thyroid-Associated
Recruiting
Phase Ⅳ
NCT02652468
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
Lymphoma
Recruiting
N/A
NCT02532192
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in A...MoreA Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Lymphoma
Withdrawn
Phase Ⅰ
NCT02763319
A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX)...MoreA Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cel Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Not yet recruiting
Phase Ⅱ/Ⅲ
NCT02792699
Study to Access if ABP798 is Safe & Effective in Treating Moderate or Severe Rheumatoid Arthritis Co...MoreStudy to Access if ABP798 is Safe & Effective in Treating Moderate or Severe Rheumatoid Arthritis Compared to Rituximab
Arthritis, Rheumatoid
Recruiting
Phase Ⅲ
NCT02356159
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell ...MoreStudy of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Myelodysplastic Syndrome/Hodgk...MoreMyelodysplastic Syndrome/Hodgkin's Lymphoma/Non-Hodgkin's Lymphoma/Acute Leukemia/Multiple Myeloma
Recruiting
Phase Ⅰ/Ⅱ
NCT02531308
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT02433795
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Marginal Zone B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT02631538
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in S...MoreSafety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
Sjogren's Syndrome
Not yet recruiting
Phase Ⅱ
NCT02790515
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depl...MoreProvision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Acute Lymphoblastic Leukemia (...MoreAcute Lymphoblastic Leukemia (ALL)/Acute Myeloid Leukemia (AML)/Myeloid Sarcoma/Chronic Myeloid Leukemia (CML)/Juvenile Myelomonocytic Leukemia (JMML)/Myelodysplastic Syndrome (MDS)/Non-Hodgkin Lymphoma (NHL)
Recruiting
Phase Ⅱ
NCT02500251
Belimumab Impacting Transplant Eligibility
Renal Transplant Rejection
Recruiting
Phase Ⅰ/Ⅱ
NCT02746744
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
Multiple Sclerosis, Relapsing-...MoreMultiple Sclerosis, Relapsing-Remitting
Not yet recruiting
Phase Ⅲ
NCT02787239
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Com...MoreClinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
B-cell Non Hodgkin's Lymphoma
Recruiting
Phase Ⅲ
NCT02571842
Rituximab in Recurrent IgA Nephropathy
Recurrent IgA Nephropathy
Recruiting
Phase Ⅳ
NCT02423915
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
Leukemia/Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02460276
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell L...MoreA Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Relapsed/Refractory Mantle Cel...MoreRelapsed/Refractory Mantle Cell Lymphoma.
Recruiting
Phase Ⅱ
NCT02623920
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-...MoreBrentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma/...MoreDiffuse Large B Cell Lymphoma/Mediastinal Large B-cell Lymphoma/Grey Zone Lymphoma/High Grade B Cell Lymphoma/Follicular Lymphoma/Marginal Zone Lymphoma/Small Lymphocytic Lymphoma
Recruiting
Phase Ⅱ
NCT02569996
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicul...MoreA Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
Lymphoma, Follicular
Completed
Phase Ⅲ
NCT02564744
IMGN529 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Fo...MoreIMGN529 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Adult Diffuse Large B-Cell Lym...MoreAdult Diffuse Large B-Cell Lymphoma/B-cell Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅱ
NCT02420938
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocy...MoreUrelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Leukemia
Recruiting
Phase Ⅱ
NCT02481297
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemi...MoreLirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Leukemia/Chronic Lymphocytic L...MoreLeukemia/Chronic Lymphocytic Leukemia/Lymphocytic Leukemia
Recruiting
Phase Ⅱ
NCT02420717
Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute ...MoreRuxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Leukemia
Recruiting
Phase Ⅱ
NCT02626845
Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Granulomatosis With Polyangiit...MoreGranulomatosis With Polyangiitis (Wegener's Granulomatosis)
Not yet recruiting
Phase Ⅳ
NCT02556866
Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis
Cryoglobulinemia/Systemic Vasc...MoreCryoglobulinemia/Systemic Vasculitis
Recruiting
Phase Ⅱ
NCT02584920
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Posi...MoreA Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
B-cell Non Hodgkin's Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT02636322
A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patie...MoreA Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT02649504
Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thr...MoreRituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
Immune Thrombocytopenia
Not yet recruiting
Phase Ⅲ
NCT02398240
Brentuximab for Newly Diagnosed Hodgkin Disease
Hodgkin Lymphoma
Recruiting
Phase Ⅱ
NCT02589145
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Trans...MoreLenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Lymphoma
Not yet recruiting
Phase Ⅰ/Ⅱ
NCT02532257
Study of Ibrutinib in Combination With Rituximab and Lenalidomide
Lymphoma/Follicular Lymphoma (...MoreLymphoma/Follicular Lymphoma (FL)
Recruiting
Phase Ⅱ
NCT02428751
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
Lymphoma, Large B-Cell, Diffus...MoreLymphoma, Large B-Cell, Diffuse
Recruiting
Phase Ⅲ
NCT02343536
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Ly...MoreA Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
Lymphoma, Large B-Cell, Diffus...MoreLymphoma, Large B-Cell, Diffuse/Lymphoma, Follicular
Recruiting
Phase Ⅰ
NCT02367040
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Lymphoma,Non-Hodgkin
Recruiting
Phase Ⅲ
NCT02481310
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymp...MoreCombination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Adult Burkitt Lymphoma/B-Cell ...MoreAdult Burkitt Lymphoma/B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma/Diffuse Large B-Cell Lymphoma/MYC Gene Mutation/Plasmablastic Lymphoma
Not yet recruiting
Phase Ⅰ/Ⅱ
NCT02533401
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
Lymphocytic Leukemia, Chronic
Completed
Phase Ⅱ
NCT02433522
Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
ANCA-associated Vasculitides
Recruiting
Phase Ⅲ
NCT02408042
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Lymphoma/Hodgkin's Lymphoma/No...MoreLymphoma/Hodgkin's Lymphoma/Non-hodgkin's Lymphoma
Withdrawn
Phase Ⅰ/Ⅱ
NCT02406092
Safety Study of Rituximab
Lymphoma
Not yet recruiting
Phase Ⅲ
NCT02438982
Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependen...MoreEfficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome
Nephrotic Syndrome
Active not recruiting
Phase Ⅳ
NCT02390362
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephr...MoreRandomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
Frequent Relapsing Nephrotic S...MoreFrequent Relapsing Nephrotic Syndrome/Steroid Dependent Nephrotic Syndrome
Recruiting
Phase Ⅲ
NCT02446236
Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidom...MoreDose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma
Recruiting
Phase Ⅰ
NCT02605694
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Lymphoma
Recruiting
Phase Ⅱ
NCT02382575
Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistan...MoreEfficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome
Nephrotic Syndrome
Recruiting
Phase Ⅳ
NCT02304354
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthri...MoreRelationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
Rheumatoid Arthritis
Recruiting
Phase Ⅲ
NCT02280525
Cord Blood Natural Killer (NK) Cells in Chronic Lymphocytic Leukemia (CLL)
Leukemia
Recruiting
Phase Ⅰ
NCT02281279
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non...MoreRituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
B-cell Adult Acute Lymphoblast...MoreB-cell Adult Acute Lymphoblastic Leukemia/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Intraocular Lymphoma/Nodal Marginal Zone B-cell Lymphoma/Recurrent Adult Acute Lymphoblastic Leukemia/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Small Lymphocytic Lymphoma/Refractory Hairy Cell Leukemia/Small Intestine Lymphoma/Splenic Marginal Zone Lymphoma/Testicular Lymphoma/Waldenström Macroglobulinemia
Not yet recruiting
Phase Ⅰ/Ⅱ
NCT02228512
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Large Cell Lymphoma Arising in...MoreLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease/Primary Effusion Lymphoma
Withdrawn
Phase Ⅰ/Ⅱ
NCT02099292
Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma
Relapsed Non-Hodgkin-Lymphoma
Completed
Phase Ⅱ
NCT02158091
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Chronic Lymphocytic Leukemia
Recruiting
Phase Ⅰ/Ⅱ
NCT02157181
Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Ri...MoreTreatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
Hairy Cell Leukemia (HCL)
Completed
Phase Ⅱ
NCT02093026
A Study to Assess the Efficacy and Safety of Retreatment With MabThera (Rituximab) in Patients With ...MoreA Study to Assess the Efficacy and Safety of Retreatment With MabThera (Rituximab) in Patients With Active Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Completed
Phase Ⅱ
NCT02257567
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendam...MoreA Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02044822
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreate...MoreEfficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Terminated
Phase Ⅱ
NCT02219737
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Larg...MoreIbrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Recurrent Diffuse Large B-Cell...MoreRecurrent Diffuse Large B-Cell Lymphoma/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅰ
NCT02043587
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymp...MoreChemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
Acute Lymphocytic Leukemia/Adu...MoreAcute Lymphocytic Leukemia/Adult Lymphoblastic Lymphoma
Recruiting
Phase Ⅱ
NCT02251964
Rituximab in Interstitial Pneumonitis
Lung Diseases, Interstitial/Pn...MoreLung Diseases, Interstitial/Pneumonitis, Interstitial
Recruiting
Phase Ⅱ/Ⅲ
NCT02031419
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma
Lymphoma, Large B-Cell, Diffus...MoreLymphoma, Large B-Cell, Diffuse
Recruiting
Phase Ⅰ
NCT02110706
Phase II Trial of Rituximab In Myasthenia Gravis
Myasthenia Gravis
Active not recruiting
Phase Ⅱ
NCT02260934
Rituximab and Belimumab for Lupus Nephritis
Lupus Nephritis
Recruiting
Phase Ⅱ
NCT02135874
A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phe...MoreA Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL)
Leukemia
Recruiting
Phase Ⅱ
NCT02049541
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Extranodal Marginal Zone B-cel...MoreExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Splenic Marginal Zone Lymphoma/Waldenström Macroglobulinemia
Recruiting
Phase Ⅰ
NCT02059239
Lymphoma Bridge Transplant Study
Hodgkin's Lymphoma/Non-Hodgkin...MoreHodgkin's Lymphoma/Non-Hodgkin's Lymphoma
Recruiting
N/A
NCT02187133
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymp...MoreCarfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Lymphoma, Non-Hodgkin/Lymphoma
Recruiting
Phase Ⅰ
NCT02199184
Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumuma...MoreBurkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)
Leukemia
Recruiting
Phase Ⅱ
NCT02258529
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymp...MoreIdelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Follicular Lymphoma/Small Lymp...MoreFollicular Lymphoma/Small Lymphocytic Lymphoma
Terminated
Phase Ⅱ
NCT02204982
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Fo...MoreStudy of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Follicular Lymphoma
Active not recruiting
Phase Ⅲ
NCT02187861
A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) ...MoreA Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma
Relapsed or Refractory Follicu...MoreRelapsed or Refractory Follicular Lymphoma
Active not recruiting
Phase Ⅱ
NCT02232386
Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymph...MorePhase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia
Chronic Lymphocyte Leukemia/Ad...MoreChronic Lymphocyte Leukemia/Adult Patients
Recruiting
Phase Ⅱ
NCT02042391
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Ritu...MoreRisk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Posttransplant Lymphoprolifera...MorePosttransplant Lymphoproliferative Disorder
Recruiting
Phase Ⅱ
NCT02200848
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Le...MorePhase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting
Phase Ⅰ
NCT02141451
INCB7839 With Rituximab After Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell...MoreINCB7839 With Rituximab After Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Non-Hodgkin Lymphoma
Diffuse Large B Cell Non-Hodgk...MoreDiffuse Large B Cell Non-Hodgkin Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02198248
Low-dose Glucocorticoid Vasculitis Induction Study
Anti-Neutrophil Cytoplasmic An...MoreAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/Microscopic Polyangiitis/Wegener Granulomatosis
Recruiting
Phase Ⅳ
NCT02079532
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Res...MoreA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT02194374
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
Leukemia
Active not recruiting
Phase Ⅰ
NCT02113007
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS)...MoreStudy of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Primary Central Nervous System...MorePrimary Central Nervous System Lymphoma
Terminated
Phase Ⅱ
NCT02203526
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxi...MorePhase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma
Primary Central Nervious Syste...MorePrimary Central Nervious System Lymphoma
Suspended
Phase Ⅰ
NCT02259348
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplan...MoreRepeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Acute Lymphoblastic Leukemia (...MoreAcute Lymphoblastic Leukemia (ALL)/Acute Myeloid Leukemia (AML)/Myeloid Sarcoma/Chronic Myelogenous Leukemia (CML)/Juvenile Myelomonocytic Leukemia (JMML)/Myelodysplastic Syndrome (MDS)/Non-Hodgkin Lymphoma (NHL)
Terminated
Phase Ⅱ
NCT02077166
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory...MoreIbrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-Cell ...MoreRelapsed Diffuse Large B-Cell Lymphoma/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02197767
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Fibrillary Glomerulonephritis
Active not recruiting
Phase Ⅱ
NCT02040116
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
Multiple Sclerosis
Completed
N/A
NCT02169219
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculiti...MorePilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Granulomatosis With Polyangiit...MoreGranulomatosis With Polyangiitis/Microscopic Polyangiitis
Recruiting
Phase Ⅳ
NCT02137681
A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of St...MoreA Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
Immune Thrombocytopenia
Withdrawn
Phase Ⅲ
NCT02073097
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell ...MoreCarfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Contiguous Stage II Adult Diff...MoreContiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02168907
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory ...MoreCPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
B-cell Adult Acute Lymphoblast...MoreB-cell Adult Acute Lymphoblastic Leukemia/B-cell Chronic Lymphocytic Leukemia/Cutaneous B-cell Non-Hodgkin Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Intraocular Lymphoma/Nodal Marginal Zone B-cell Lymphoma/Recurrent Adult Acute Lymphoblastic Leukemia/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Mycosis Fungoides/Sezary Syndrome/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Refractory Hairy Cell Leukemia/Small Intestine Lymphoma/Splenic Marginal Zone Lymphoma/Testicular Lymphoma/Waldenström Macroglobulinemia
Recruiting
Phase Ⅰ
NCT02165397
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Waldenström's Macroglobulinemi...MoreWaldenström's Macroglobulinemia
Active not recruiting
Phase Ⅲ
NCT02253264
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
Primary Progressive Multiple S...MorePrimary Progressive Multiple Sclerosis/Secondary Progressive Multiple Sclerosis
Recruiting
Phase Ⅰ
NCT02160015
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymp...MoreLenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic ...MoreRecurrent Chronic Lymphocytic Leukemia/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Refractory Small Lymphocytic Lymphoma
Suspended
Phase Ⅰ
NCT02055820
A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02097745
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoi...MoreA Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT02257242
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indol...MoreVincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Lymphoma, Non-Hodgkin/Lymphoma...MoreLymphoma, Non-Hodgkin/Lymphoma, Follicular/Lymphoma, Mantle-Cell/Lymphoma, Small-Cell/Waldenstrom Macroglobulinemia/Lymphoma, B-Cell, Marginal Zone
Not yet recruiting
Phase Ⅰ
NCT02060656
Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma...MorePhase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT02267915
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and ...MorePhase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
Mantle-cell Lymphoma
Recruiting
Phase Ⅱ
NCT02251548
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lympho...MoreA Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia/L...MoreChronic Lymphocytic Leukemia/Leukemia
Recruiting
Phase Ⅱ
NCT02229942
B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME)....MoreB-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.
Chronic Fatigue Syndrome/ Myal...MoreChronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME)
Active not recruiting
Phase Ⅲ
NCT02115997
A Study Evaluating the Safety and Efficacy of Ristova (Rituximab) in Combination With Glucocorticoid...MoreA Study Evaluating the Safety and Efficacy of Ristova (Rituximab) in Combination With Glucocorticoids in Patients With Wegener's Granulomatosis or Microscopic Polyangitis
Wegener's Granulomatosis, Micr...MoreWegener's Granulomatosis, Microscopic Polyangiitis
Recruiting
Phase Ⅳ
NCT02180711
An Open-label, Phase 1b Study of ACP 196 Alone or in Combination With Rituximab in Subjects With Fol...MoreAn Open-label, Phase 1b Study of ACP 196 Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma
Follicular Lymphoma (FL)
Recruiting
Phase Ⅰ
NCT02048813
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Trea...MoreIbrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Anemia/Fever, Sweat, and Hot F...MoreAnemia/Fever, Sweat, and Hot Flashes/Stage I Chronic Lymphocytic Leukemia/Stage I Small Lymphocytic Lymphoma/Stage II Chronic Lymphocytic Leukemia/Stage II Small Lymphocytic Lymphoma/Stage III Chronic Lymphocytic Leukemia/Stage III Small Lymphocytic Lymphoma/Stage IV Chronic Lymphocytic Leukemia/Stage IV Small Lymphocytic Lymphoma/Weight Change
Active not recruiting
Phase Ⅲ
NCT02086175
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Relapsed/Refractory Indolent B...MoreRelapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Recruiting
Phase Ⅱ
NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Ce...MoreLenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Adult Grade III Lymphomatoid G...MoreAdult Grade III Lymphomatoid Granulomatosis/B-cell Chronic Lymphocytic Leukemia/Contiguous Stage II Adult Diffuse Large Cell Lymphoma/Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma/Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma/Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma/Contiguous Stage II Grade 1 Follicular Lymphoma/Contiguous Stage II Grade 2 Follicular Lymphoma/Contiguous Stage II Grade 3 Follicular Lymphoma/Contiguous Stage II Mantle Cell Lymphoma/Contiguous Stage II Marginal Zone Lymphoma/Contiguous Stage II Small Lymphocytic Lymphoma/Cutaneous B-cell Non-Hodgkin Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Intraocular Lymphoma/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma/Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma/Noncontiguous Stage II Grade 1 Follicular Lymphoma/Noncontiguous Stage II Grade 2 Follicular Lymphoma/Noncontiguous Stage II Grade 3 Follicular Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Noncontiguous Stage II Marginal Zone Lymphoma/Noncontiguous Stage II Small Lymphocytic Lymphoma/Progressive Hairy Cell Leukemia, Initial Treatment/Small Intestine Lymphoma/Splenic Marginal Zone Lymphoma/Stage 0 Chronic Lymphocytic Leukemia/Stage I Adult Diffuse Large Cell Lymphoma/Stage I Adult Diffuse Mixed Cell Lymphoma/Stage I Adult Diffuse Small Cleaved Cell Lymphoma/Stage I Adult Hodgkin Lymphoma/Stage I Adult Immunoblastic Large Cell Lymphoma/Stage I Chronic Lymphocytic Leukemia/Stage I Grade 1 Follicular Lymphoma/Stage I Grade 2 Follicular Lymphoma/Stage I Grade 3 Follicular Lymphoma/Stage I Mantle Cell Lymphoma/Stage I Marginal Zone Lymphoma/Stage I Small Lymphocytic Lymphoma/Stage II Adult Hodgkin Lymphoma/Stage II Chronic Lymphocytic Leukemia/Stage II Small Lymphocytic Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Mixed Cell Lymphoma/Stage III Adult Diffuse Small Cleaved Cell Lymphoma/Stage III Adult Hodgkin Lymphoma/Stage III Adult Immunoblastic Large Cell Lymphoma/Stage III Chronic Lymphocytic Leukemia/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage III Mantle Cell Lymphoma/Stage III Marginal Zone Lymphoma/Stage III Small Lymphocytic Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Mixed Cell Lymphoma/Stage IV Adult Diffuse Small Cleaved Cell Lymphoma/Stage IV Adult Hodgkin Lymphoma/Stage IV Adult Immunoblastic Large Cell Lymphoma/Stage IV Chronic Lymphocytic Leukemia/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Grade 3 Follicular Lymphoma/Stage IV Mantle Cell Lymphoma/Stage IV Marginal Zone Lymphoma/Stage IV Small Lymphocytic Lymphoma/Testicular Lymphoma/Untreated Hairy Cell Leukemia/Waldenström Macroglobulinemia
Recruiting
Phase Ⅰ/Ⅱ
NCT02128061
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of ...MoreEfficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
Diffuse Large B Cell Lymphoma
Recruiting
Phase Ⅲ
NCT01959698
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or...MoreCarfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Contiguous Stage II Adult Diff...MoreContiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT02013817
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Ch...MoreCHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Lymphocytic Leukemia, Chronic
Completed
Phase Ⅱ
NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Adult Grade III Lymphomatoid G...MoreAdult Grade III Lymphomatoid Granulomatosis/Adult Nasal Type Extranodal NK/T-cell Lymphoma/Anaplastic Large Cell Lymphoma/Angioimmunoblastic T-cell Lymphoma/Contiguous Stage II Adult Burkitt Lymphoma/Contiguous Stage II Adult Diffuse Large Cell Lymphoma/Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma/Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma/Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma/Contiguous Stage II Adult Lymphoblastic Lymphoma/Contiguous Stage II Grade 1 Follicular Lymphoma/Contiguous Stage II Grade 2 Follicular Lymphoma/Contiguous Stage II Grade 3 Follicular Lymphoma/Contiguous Stage II Mantle Cell Lymphoma/Contiguous Stage II Marginal Zone Lymphoma/Contiguous Stage II Small Lymphocytic Lymphoma/Cutaneous B-cell Non-Hodgkin Lymphoma/Epstein-Barr Virus Infection/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Hepatosplenic T-cell Lymphoma/Intraocular Lymphoma/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Adult Burkitt Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma/Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma/Noncontiguous Stage II Adult Lymphoblastic Lymphoma/Noncontiguous Stage II Grade 1 Follicular Lymphoma/Noncontiguous Stage II Grade 2 Follicular Lymphoma/Noncontiguous Stage II Grade 3 Follicular Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Noncontiguous Stage II Marginal Zone Lymphoma/Noncontiguous Stage II Small Lymphocytic Lymphoma/Noncutaneous Extranodal Lymphoma/Peripheral T-cell Lymphoma/Post-transplant Lymphoproliferative Disorder/Progressive Hairy Cell Leukemia, Initial Treatment/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Hodgkin Lymphoma/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Adult T-cell Leukemia/Lymphoma/Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Mycosis Fungoides/Sezary Syndrome/Recurrent Small Lymphocytic Lymphoma/Refractory Hairy Cell Leukemia/Small Intestine Lymphoma/Splenic Marginal Zone Lymphoma/Stage I Adult Burkitt Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage I Adult Diffuse Mixed Cell Lymphoma/Stage I Adult Diffuse Small Cleaved Cell Lymphoma/Stage I Adult Hodgkin Lymphoma/Stage I Adult Immunoblastic Large Cell Lymphoma/Stage I Adult Lymphoblastic Lymphoma/Stage I Adult T-cell Leukemia/Lymphoma/Stage I Cutaneous T-cell Non-Hodgkin Lymphoma/Stage I Grade 1 Follicular Lymphoma/Stage I Grade 2 Follicular Lymphoma/Stage I Grade 3 Follicular Lymphoma/Stage I Mantle Cell Lymphoma/Stage I Marginal Zone Lymphoma/Stage I Small Lymphocytic Lymphoma/Stage IA Mycosis Fungoides/Sezary Syndrome/Stage IB Mycosis Fungoides/Sezary Syndrome/Stage II Adult Hodgkin Lymphoma/Stage II Adult T-cell Leukemia/Lymphoma/Stage II Cutaneous T-cell Non-Hodgkin Lymphoma/Stage IIA Mycosis Fungoides/Sezary Syndrome/Stage IIB Mycosis Fungoides/Sezary Syndrome/Stage III Adult Burkitt Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Mixed Cell Lymphoma/Stage III Adult Diffuse Small Cleaved Cell Lymphoma/Stage III Adult Hodgkin Lymphoma/Stage III Adult Immunoblastic Large Cell Lymphoma/Stage III Adult Lymphoblastic Lymphoma/Stage III Adult T-cell Leukemia/Lymphoma/Stage III Cutaneous T-cell Non-Hodgkin Lymphoma/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage III Mantle Cell Lymphoma/Stage III Marginal Zone Lymphoma/Stage III Small Lymphocytic Lymphoma/Stage IIIA Mycosis Fungoides/Sezary Syndrome/Stage IIIB Mycosis Fungoides/Sezary Syndrome/Stage IV Adult Burkitt Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Mixed Cell Lymphoma/Stage IV Adult Diffuse Small Cleaved Cell Lymphoma/Stage IV Adult Hodgkin Lymphoma/Stage IV Adult Immunoblastic Large Cell Lymphoma/Stage IV Adult Lymphoblastic Lymphoma/Stage IV Adult T-cell Leukemia/Lymphoma/Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Grade 3 Follicular Lymphoma/Stage IV Mantle Cell Lymphoma/Stage IV Marginal Zone Lymphoma/Stage IV Small Lymphocytic Lymphoma/Stage IVA Mycosis Fungoides/Sezary Syndrome/Stage IVB Mycosis Fungoides/Sezary Syndrome/T-cell Large Granular Lymphocyte Leukemia/Testicular Lymphoma/Untreated Hairy Cell Leukemia/Waldenström Macroglobulinemia
Recruiting
Phase Ⅰ/Ⅱ
NCT01848132
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lym...MoreEfficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Diffuse, Large B-Cell, Lymphom...MoreDiffuse, Large B-Cell, Lymphoma
Active not recruiting
Phase Ⅱ
NCT01811368
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Refractory Non Hodgkin Lymphom...MoreRefractory Non Hodgkin Lymphoma/Relapsed Non Hodgkin Lymphoma
Recruiting
Phase Ⅱ
NCT01955187
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy
MEMBRANOUS NEPHROPATHY
Recruiting
Phase Ⅲ
NCT01812005
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hod...MoreAlisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cel...MoreExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Splenic Marginal Zone Lymphoma/Waldenström Macroglobulinemia
Active not recruiting
Phase Ⅱ
NCT01933711
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Ly...MoreRituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
CD20+ Aggressive Lymphoma, Man...MoreCD20+ Aggressive Lymphoma, Mantle Cell Lymphoma
Active not recruiting
Phase Ⅲ
NCT01862926
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Interstitial Lung Disease/Scle...MoreInterstitial Lung Disease/Scleroderma/Idiopathic Inflammatory Myositis/Mixed Connective Tissue Disease
Recruiting
Phase Ⅱ/Ⅲ
NCT01980654
Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreate...MoreStudy of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Follicular Lymphoma/B-cell Lym...MoreFollicular Lymphoma/B-cell Lymphoma/Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅱ
NCT01996865
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refra...MoreLenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Recruiting
Phase Ⅲ
NCT01956695
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System L...MoreEfficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
Lymphoma/Relapse/Lenalidomide/...MoreLymphoma/Relapse/Lenalidomide/Rituximab
Active not recruiting
Phase Ⅱ
NCT02007044
Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leuke...MoreIbrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Leukemia
Recruiting
Phase Ⅱ
NCT01808599
This Trial is a Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranoda...MoreThis Trial is a Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
MALT Lymphoma
Recruiting
Phase Ⅱ
NCT01983969
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Advanced Cancers/Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01829958
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lympho...MoreComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
Non Hodgkin Lymphoma (NHL)/Dif...MoreNon Hodgkin Lymphoma (NHL)/Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting
N/A
NCT01998893
A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodg...MoreA Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT01830478
Lenalidomide Plus Rituximab (R) in Non Follicular NHL
Indolent Non Hodgkin Lymphoma
Active not recruiting
Phase Ⅱ
NCT01980888
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Pr...MoreEfficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅲ
NCT02005471
A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabT...MoreA Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅲ
NCT01973387
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphom...MoreA Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active not recruiting
Phase Ⅲ
NCT01987505
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Adminis...MoreMabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Mabthera/Rituxan During First-Line Treatment for Lymphoma.
Lymphoma, Non Hodgkin
Active not recruiting
Phase Ⅲ
NCT01855750
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituxi...MoreA Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Lymphoma
Active not recruiting
Phase Ⅲ
NCT01776840
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine a...MoreA Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Mantle Cell Lymphoma
Active not recruiting
Phase Ⅲ
NCT01868269
Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblast...MoreOpsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)
Opsoclonus Myoclonus Syndrome/...MoreOpsoclonus Myoclonus Syndrome/Neuroblastoma
Recruiting
Phase Ⅲ
NCT01939327
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
Non-Hodgkin Lymphoma
Recruiting
Phase Ⅱ
NCT01873443
Long-Term Efficacy and Safety of CT-P10 in Patients With RA
Rheumatoid Arthritis
Completed
Phase Ⅰ
NCT01925612
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Di...MoreStudy of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Lymphoma, B-cell/Lymphoma, Lar...MoreLymphoma, B-cell/Lymphoma, Large B-cell, Diffuse
Recruiting
Phase Ⅱ
NCT01813227
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Waldenstrom/Prior Bortezomib T...MoreWaldenstrom/Prior Bortezomib Therapy Acceptable.
Active not recruiting
Phase Ⅱ
NCT01780454
Renal Allograft Tolerance Through Mixed Chimerism
End Stage Renal Disease
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01992653
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxo...MoreA Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Lymphoma, B-Cell, Non-Hodgkin'...MoreLymphoma, B-Cell, Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅰ
NCT01871675
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Lymphoma/Chronic Lymphocytic L...MoreLymphoma/Chronic Lymphocytic Leukemia/Non-Hodgkin Lymphoma/T-cell Lymphoma
Active not recruiting
Phase Ⅰ
NCT01969409
Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis
Ambulatory IPF
Recruiting
Phase Ⅱ
NCT01974518
Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in S...MoreComparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
Pemphigus
Active not recruiting
Phase Ⅲ
NCT01880567
Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Lymphoma
Recruiting
Phase Ⅱ
NCT01788020
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Waldenström's Macroglobulinemi...MoreWaldenström's Macroglobulinemia
Recruiting
Phase Ⅲ
NCT01998880
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untr...MoreCLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
Lymphocytic Leukemia, Chronic
Active not recruiting
Phase Ⅲ
NCT01842386
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Anticytokine Autoantibody-Asso...MoreAnticytokine Autoantibody-Associated Diseases/Disseminated Non-Tuberculous Mycobacteria/Chronic Mucocutaneous Candidiasis/Pulmonary Alveolar Proteinosis (PAP)
Recruiting
Phase Ⅰ
NCT01865110
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Pat...MoreR-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
Mantle Cell Lymphoma
Recruiting
Phase Ⅲ
NCT01859819
Treatment for Advanced B-Cell Lymphoma
Diffuse Large Cell Lymphoma/Bu...MoreDiffuse Large Cell Lymphoma/Burkitt's Lymphoma/High Grade B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT01829568
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Fo...MoreRituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
Stage II Grade 1 Contiguous Fo...MoreStage II Grade 1 Contiguous Follicular Lymphoma/Stage II Grade 1 Non-Contiguous Follicular Lymphoma/Stage II Grade 2 Contiguous Follicular Lymphoma/Stage II Grade 2 Non-Contiguous Follicular Lymphoma/Stage II Grade 3 Contiguous Follicular Lymphoma/Stage II Grade 3 Non-Contiguous Follicular Lymphoma/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Grade 3 Follicular Lymphoma
Active not recruiting
Phase Ⅰ
NCT02006706
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid...MoreA Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT01939730
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT01902862
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in P...MoreAn Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
Lymphoma, Follicular
Terminated
Phase Ⅱ
NCT01974440
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab,...MoreA Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Lymphoma
Active not recruiting
Phase Ⅲ
NCT01856192
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly ...MoreRituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Stage II Diffuse Large B-Cell ...MoreStage II Diffuse Large B-Cell Lymphoma/Stage III Diffuse Large B-Cell Lymphoma/Stage IV Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01938001
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma ...MoreRituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Recruiting
Phase Ⅲ
NCT01886872
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Ol...MoreRituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Le...MoreStage I Chronic Lymphocytic Leukemia/Stage II Chronic Lymphocytic Leukemia/Stage III Chronic Lymphocytic Leukemia/Stage IV Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅲ
NCT01851551
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Non-Hodgkin's Lymphoma/Diffuse...MoreNon-Hodgkin's Lymphoma/Diffuse Large B-cell Lymphoma/Mantle Cell Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT01832922
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active not recruiting
Phase Ⅰ
NCT01831505
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agen...MoreFeasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Lymphoma
Active not recruiting
Phase Ⅰ
NCT01990144
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL...MoreRituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT01779167
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
Waldenstrom Macroglobulinemia
Terminated
Phase Ⅱ
NCT02053610
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Unt...MoreCLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
Lymphocytic Leukemia, Chronic
Active not recruiting
Phase Ⅲ
NCT01691898
A Safety and Efficacy Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab (MabThera/Rit...MoreA Safety and Efficacy Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab (MabThera/Rituxan) or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab and Polatuzumab Vedotin Combined With Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)
Diffuse Large B-Cell Lymphoma,...MoreDiffuse Large B-Cell Lymphoma, Lymphoma, Follicular
Recruiting
Phase Ⅰ/Ⅱ
NCT01734057
Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Init...MoreRecombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Purpura/Idiopathic Thrombocyto...MorePurpura/Idiopathic Thrombocytopenic Purpura
Withdrawn
Phase Ⅲ
NCT01520519
Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in Hi...MorePhase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
Leukemia
Active not recruiting
Phase Ⅱ
NCT01754857
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Ri...MorePhase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Lymphoid Leukemia/Small Lympho...MoreLymphoid Leukemia/Small Lymphocytic Lymphoma/Lymphoma, Non-Hodgkin
Recruiting
Phase Ⅱ
NCT01649856
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Che...MoreA Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Lymphoma, Large B-Cell, Diffus...MoreLymphoma, Large B-Cell, Diffuse
Active not recruiting
Phase Ⅲ
NCT01516580
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute ...MoreIntergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
B-cell Non Hodgkin Lymphoma/Ma...MoreB-cell Non Hodgkin Lymphoma/Mature B-cell Leukemia Burkitt-type
Recruiting
Phase Ⅲ
NCT01539174
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-...MoreRituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
Contiguous Stage II Adult Diff...MoreContiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma
Withdrawn
Phase Ⅱ
NCT01678404
131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
Relapsed or Refractory Margina...MoreRelapsed or Refractory Marginal Zone B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT01560117
Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintena...MoreCombination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma
Follicular T-NHL Lymphoma/Ritu...MoreFollicular T-NHL Lymphoma/Rituximab Maintenance
Completed
Phase Ⅱ
NCT01671904
A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in P...MoreA Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Recruiting
Phase Ⅰ
NCT01676558
A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed or Refractory Diffuse...MoreRelapsed or Refractory Diffuse Large B Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01716442
Rituximab Trial for Pediatric Nephrotic Syndrome
Steroid Resistant Nephrotic Sy...MoreSteroid Resistant Nephrotic Syndrome/Steroid Dependent Nephrotic Syndrome
Recruiting
Phase Ⅱ/Ⅲ
NCT01525836
rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
Purpura/Idiopathic Thrombocyto...MorePurpura/Idiopathic Thrombocytopenic Purpura
Completed
Phase Ⅲ
NCT01593332
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients Wi...MoreLow Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
DMARD Resistant Rheumatoid Art...MoreDMARD Resistant Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT01702038
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People Wit...MoreDetermining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
Lupus Erythematosus, Systemic
Withdrawn
Phase Ⅱ
NCT01729104
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantl...MorePhase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT01524068
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis ...MoreA MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
Idiopathic Pulmonary Fibrosis
Withdrawn
Phase Ⅱ
NCT01670812
Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Recruiting
Phase Ⅲ
NCT01744626
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic...MoreSafety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Leukemia Lymphocytic Chronic B...MoreLeukemia Lymphocytic Chronic B-Cell
Completed
Phase Ⅰ
NCT01686321
Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggre...MoreRituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
Aggressive Lymphoma
Recruiting
Phase Ⅱ
NCT01539512
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for...MoreA Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Completed
Phase Ⅲ
NCT01719159
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
Progressive Multiple Sclerosis
Recruiting
Phase Ⅱ
NCT01731561
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
Granulomatosis With Polyangiit...MoreGranulomatosis With Polyangiitis/Microscopic Polyangiitis/Renal Limited Forms
Active not recruiting
Phase Ⅲ
NCT01695941
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Ly...MoreAlisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin L...MoreRecurrent B-Cell Non-Hodgkin Lymphoma/Recurrent Mantle Cell Lymphoma/Refractory B-Cell Non-Hodgkin Lymphoma/Refractory Mantle Cell Lymphoma
Recruiting
Phase Ⅰ
NCT01719692
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
Immune Thrombocytopenic Purpur...MoreImmune Thrombocytopenic Purpura
Recruiting
N/A
NCT01538641
Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive ...MorePhase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas
Refractory Aggressive Non-Hodg...MoreRefractory Aggressive Non-Hodgkin's Lymphoma/Relapsing Aggressive Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT01569295
A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamusti...MoreA Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅲ
NCT01750697
A Study of Intravenous MabThera/Rituxan in Pediatric Patients With Severe Granulomatosis With Polyan...MoreA Study of Intravenous MabThera/Rituxan in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Wegener's Granulomatosis, Micr...MoreWegener's Granulomatosis, Microscopic Polyangiitis
Recruiting
Phase Ⅱ
NCT01682512
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
Arthritis, Rheumatoid
Active not recruiting
Phase Ⅲ
NCT01723839
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomi...MorePhase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
Chronic Lymphocytic Leukemia (...MoreChronic Lymphocytic Leukemia (CLL)
Active not recruiting
Phase Ⅱ
NCT01619761
Natural Killer (NK) Cells in Cord Blood Transplantation
Leukemia/Chronic Lymphocytic L...MoreLeukemia/Chronic Lymphocytic Leukemia
Recruiting
Phase Ⅰ
NCT01611090
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Ref...MoreA Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active not recruiting
Phase Ⅲ
NCT01737177
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractor...MoreBendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
Mantle Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01662102
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Follicular Lymphoma
Terminated
Phase Ⅲ
NCT01650701
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidom...MoreA Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
Follicular Lymphoma
Active not recruiting
Phase Ⅲ
NCT01661881
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Mantle Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT01509300
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute L...MoreHLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
Acute Leukemia/Myelodysplastic...MoreAcute Leukemia/Myelodysplastic Syndrome/Solid Tumors
Recruiting
Phase Ⅰ/Ⅱ
NCT01662050
Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Pat...MorePhase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma
Mantle Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT01759030
Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Active not recruiting
Phase Ⅲ
NCT01625741
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptim...MorePhase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
Chronic Lymphocytic Leukemia
Terminated
Phase Ⅱ
NCT01724021
A Study of Patient Preference With Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in P...MoreA Study of Patient Preference With Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Patients With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Diffuse Large B-Cell Lymphoma,...MoreDiffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅲ
NCT01665768
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
CD20+, B-cell Lymphomas/Mantle...MoreCD20+, B-cell Lymphomas/Mantle Cell Lymphoma/Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL)/Transformed Lymphoma/DLBCL/PMBCL/Hodgkin's Disease/Gray Zone Lymphoma
Recruiting
Phase Ⅱ
NCT01650727
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemi...MoreA Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Completed
Phase Ⅰ
NCT01576588
Rituximab in Pretreated Elderly or Unfit B-CLL Patients
B-Cell Chronic Lymphocytic Leu...MoreB-Cell Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅱ
NCT01718691
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Lo...MoreEfficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Low-grade B Cell Non-Hodgkin's...MoreLow-grade B Cell Non-Hodgkin's Lymphoma/Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Completed
Phase Ⅱ
NCT01584388
Rituximab in IgG4-related Disease: A Phase 1-2 Trial
Retroperitoneal Fibrosis/Autoi...MoreRetroperitoneal Fibrosis/Autoimmune Pancreatitis/Sialadenitis/Pseudotumor
Completed
Phase Ⅰ/Ⅱ
NCT01622439
Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymph...MoreValproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT01810926
T&B Depletion Non Malignant
Graft Versus Host Disease
Recruiting
Phase Ⅱ
NCT01679119
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Cont...MoreTreatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
Diffuse Large B Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01556347
Multi-Drug Desensitization Protocol for Heart Transplant Candidates
Heart Transplantation
Recruiting
Phase Ⅱ
NCT01514344
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma
Ocular Adnexal Mucosa-Associat...MoreOcular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Recruiting
Phase Ⅱ
NCT01701986
Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT01569451
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Aceta...MoreComparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy for MS
Multiple Sclerosis
Completed
Phase Ⅱ
NCT01808911
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined ...MoreOutcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Acquired Haemophilia
Recruiting
Phase Ⅲ
NCT01542918
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Recurrent/Refractory CNS/Intra...MoreRecurrent/Refractory CNS/Intraocular Lymphoma
Recruiting
Phase Ⅰ
NCT01516567
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOC...MoreIntergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
Primary Mediastinal Large B Ce...MorePrimary Mediastinal Large B Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01697267
Rituximab Vasculitis Maintenance Study
Anti-Neutrophil Cytoplasmic An...MoreAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/Microscopic Polyangiitis/Wegener Granulomatosis
Recruiting
Phase Ⅲ
NCT01678417
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Relapsed or Refractory Follicu...MoreRelapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01595048
Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV No...MoreCombination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Childhood B Acute Lymphoblasti...MoreChildhood B Acute Lymphoblastic Leukemia/Childhood Burkitt Leukemia/Childhood Diffuse Large Cell Lymphoma/Mediastinal (Thymic) Large B-Cell Lymphoma/Stage III Childhood Large Cell Lymphoma/Stage IV Childhood Large Cell Lymphoma
Active not recruiting
Phase Ⅱ/Ⅲ
NCT01748084
Rituximab in Systemic Sclerosis
Systemic Sclerosis
Active not recruiting
Phase Ⅱ/Ⅲ
NCT01686165
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Anaplastic Large Cell Lymphoma...MoreAnaplastic Large Cell Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Mantle Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT01700946
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymph...MoreTherapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acu...MoreRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia/Recurrent Childhood B-Lymphoblastic Lymphoma
Recruiting
Phase Ⅱ
NCT01609010
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Fol...MoreA Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT01760226
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
Diffuse Large B Cell Lymphoma/...MoreDiffuse Large B Cell Lymphoma/Post Transplant Lymphoproliferative Disorder/Primary Mediastinal (Thymic) Large B-cell Lymphoma
Recruiting
N/A
NCT01773616
Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis
Systemic Lupus Erythematosus, ...MoreSystemic Lupus Erythematosus, Lupus Nephritis
Recruiting
Phase Ⅲ
NCT01592981
Randomised Trial in Waldenstrom's Macroglobulinaemia
Waldenstrom's Macroglobulinaem...MoreWaldenstrom's Macroglobulinaemia
Active not recruiting
Phase Ⅱ
NCT01713738
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Pur...MoreClinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Pu...MoreIdiopathic Thrombocytopenic Purpura (ITP)/Immune Thrombocytopenic Purpura (ITP)
Completed
Phase Ⅰ/Ⅱ
NCT01732913
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Ind...MoreEfficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Indolent Non-Hodgkin's Lymphom...MoreIndolent Non-Hodgkin's Lymphomas
Terminated
Phase Ⅲ
NCT01594229
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Ritux...MoreA Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅰ
NCT01598558
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
Non-Hodgkin's Lymphoma
Withdrawn
N/A
NCT01562990
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-c...MorePhase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
Diffuse Large B-Cell Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT01754870
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Ri...MorePhase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia (...MoreChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Withdrawn
Phase Ⅱ
NCT01611259
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
Lymphoma of the Mucosa Associa...MoreLymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Completed
Phase Ⅱ
NCT01670084
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromo...MoreNilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
B-cell Adult Acute Lymphoblast...MoreB-cell Adult Acute Lymphoblastic Leukemia/Blastic Phase Chronic Myelogenous Leukemia/Chronic Myelogenous Leukemia, BCR-ABL1 Positive/Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia/Untreated Adult Acute Lymphoblastic Leukemia
Withdrawn
Phase Ⅱ
NCT01732926
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previ...MoreEfficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Indolent Non-Hodgkin's Lymphom...MoreIndolent Non-Hodgkin's Lymphomas
Terminated
Phase Ⅲ
NCT01664910
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Lymphoma/Leukemia
Recruiting
Phase Ⅰ/Ⅱ
NCT01596127
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
Leukemia/Lymphoid Malignancies...MoreLeukemia/Lymphoid Malignancies/Metastatic Malignant Neoplasm to the Leptomeninges
Recruiting
Phase Ⅰ/Ⅱ
NCT01682616
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in ...MoreA Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma/Chr...MoreSmall Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅰ
NCT01653067
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01278745
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplant...MorePrevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
Cardiac Allograft Vasculopathy
Terminated
Phase Ⅱ
NCT01508468
Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy
Idiopathic Membranous Nephropa...MoreIdiopathic Membranous Nephropathy
Active not recruiting
Phase Ⅲ
NCT01307267
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Lymphoma, Non-Hodgkin/Lymphoma...MoreLymphoma, Non-Hodgkin/Lymphoma, Follicular/Lymphoma, Large B-Cell, Diffuse/Carcinoma, Non-Small-Cell Lung/Carcinoma, Renal Cell/Carcinoma, Squamous Cell of Head and Neck
Recruiting
Phase Ⅰ
NCT01461928
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Pat...MoreA Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅳ
NCT01424982
Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Leukemia
Recruiting
Phase Ⅱ
NCT01408342
Alemtuzumab and Rituximab in Aplastic Anemia
Aplastic Anemia
Withdrawn
N/A
NCT01453205
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refracto...MoreA Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma ...MoreDiffuse Large B-Cell Lymphoma (DLBCL)
Active not recruiting
Phase Ⅱ
NCT01332968
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab...MoreA Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅲ
NCT01392716
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT01282476
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT01390441
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 EXT 1)
Rheumatoid Arthritis
Completed
Phase Ⅰ
NCT01466153
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic L...MoreA Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (...MoreChronic Lymphocytic Leukemia (CLL)
Completed
Phase Ⅱ
NCT01506414
Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
Purpura/Idiopathic Thrombocyto...MorePurpura/Idiopathic Thrombocytopenic Purpura
Completed
Phase Ⅲ
NCT01290549
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins...MoreA Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma, Chroni...MoreNon-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Completed
Phase Ⅰ
NCT01388959
A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT01470456
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Completed
Phase Ⅱ
NCT01491841
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT01490723
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Leukemia/Lymphoma
Active not recruiting
Phase Ⅱ
NCT01292603
A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemothe...MoreA Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Active not recruiting
Phase Ⅰ
NCT01476787
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Follicular Lymphoma
Active not recruiting
Phase Ⅲ
NCT01415752
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Trea...MoreRituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Lymphoma/Neurotoxicity/Therapy...MoreLymphoma/Neurotoxicity/Therapy-related Toxicity
Recruiting
Phase Ⅱ
NCT01521689
Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅱ
NCT01448096
Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma
Large B Cell Diffuse Lymphoma
Recruiting
Phase Ⅱ
NCT01317901
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent...MoreA Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
B-cell Small Lymphocytic Lymph...MoreB-cell Small Lymphocytic Lymphoma Recurrent
Completed
Phase Ⅰ
NCT01303887
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Pati...MoreA Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
Follicular Lymphoma
Recruiting
Phase Ⅲ
NCT01312064
De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction
Renal Insufficiency
Terminated
Phase Ⅳ
NCT01421173
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or ...MoreVorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Lymphoma
Completed
Phase Ⅰ
NCT01482754
Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma
Non Hodgkin Lymphoma
Completed
N/A
NCT01287741
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (R...MoreA Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Lymphoma, B-Cell
Active not recruiting
Phase Ⅲ
NCT01307605
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lym...MoreRituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT01523860
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Folli...MoreBrief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
Follicular Lymphoma
Completed
Phase Ⅱ
NCT01427114
R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)
Lymphoma
Active not recruiting
Phase Ⅱ
NCT01493479
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial T...MorePhase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma
Follicular Lymphoma
Active not recruiting
Phase Ⅱ
NCT01334502
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untrea...MoreEverolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Lymphoma
Active not recruiting
Phase Ⅰ
NCT01319981
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Leukemia
Recruiting
Phase Ⅱ
NCT01307592
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relaps...MoreGemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT01283386
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambuc...MoreA Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status
Lymphocytic Leukemia, Chronic
Completed
Phase Ⅳ
NCT01318317
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Pa...MoreGenetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
Recurrent Adult Diffuse Large ...MoreRecurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01332994
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed...MoreA Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT01558167
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomid in Patients ...MoreA Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomid in Patients With Chronic Lymphocytic Leukemia
Chronic Lymphatic Leukemia
Terminated
Phase Ⅰ/Ⅱ
NCT01439750
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Mantle Cell Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT01419795
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lym...MoreLenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Adult Nasal Type Extranodal NK...MoreAdult Nasal Type Extranodal NK/T-cell Lymphoma/Anaplastic Large Cell Lymphoma/Angioimmunoblastic T-cell Lymphoma/Cutaneous B-cell Non-Hodgkin Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Hepatosplenic T-cell Lymphoma/Intraocular Lymphoma/Nodal Marginal Zone B-cell Lymphoma/Noncutaneous Extranodal Lymphoma/Peripheral T-cell Lymphoma/Prolymphocytic Leukemia/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Adult T-cell Leukemia/Lymphoma/Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Mycosis Fungoides/Sezary Syndrome/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Refractory Hairy Cell Leukemia/Small Intestine Lymphoma/Splenic Marginal Zone Lymphoma/T-cell Large Granular Lymphocyte Leukemia/Testicular Lymphoma/Waldenström Macroglobulinemia
Terminated
Phase Ⅱ
NCT01272908
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior A...MoreA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT01472562
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT01434472
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regim...MoreHigh-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Post-Transplant Lymphoprolifer...MorePost-Transplant Lymphoproliferative Disorder/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent B-Cell Non-Hodgkin Lymphoma/Recurrent Burkitt Lymphoma/Refractory B-Cell Non-Hodgkin Lymphoma/Refractory Burkitt Lymphoma/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01382940
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Ar...MoreA Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT01309997
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Di...MoreImatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
Graft Versus Host Disease/Syst...MoreGraft Versus Host Disease/Systemic Scleroderma
Completed
Phase Ⅱ
NCT01321541
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell...MoreComparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Diffuse Large B-cell Lymphoma/...MoreDiffuse Large B-cell Lymphoma/de Novo DLBCL/DLBCL Transformed From Indolent Lymphoma/Follicular Grade 3 Lymphoma
Recruiting
Phase Ⅲ
NCT01470196
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Active not recruiting
Phase Ⅱ
NCT01326702
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractor...MoreVeliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Adult B Acute Lymphoblastic Le...MoreAdult B Acute Lymphoblastic Leukemia/Adult Nasal Type Extranodal NK/T-Cell Lymphoma/Adult Solid Neoplasm/Anaplastic Large Cell Lymphoma/Angioimmunoblastic T-Cell Lymphoma/Chronic Lymphocytic Leukemia/Cutaneous B-Cell Non-Hodgkin Lymphoma/Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue/Hepatosplenic T-Cell Lymphoma/Intraocular Lymphoma/Lymphomatous Involvement of Non-Cutaneous Extranodal Site/Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma/Nodal Marginal Zone Lymphoma/Recurrent Adult Acute Lymphoblastic Leukemia/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Hodgkin Lymphoma/Recurrent Adult Immunoblastic Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Adult T-Cell Leukemia/Lymphoma/Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Mycosis Fungoides and Sezary Syndrome/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Refractory Hairy Cell Leukemia/Refractory Plasma Cell Myeloma/Small Intestinal Lymphoma/Splenic Marginal Zone Lymphoma/Testicular Lymphoma/Waldenstrom Macroglobulinemia
Completed
Phase Ⅰ/Ⅱ
NCT01429025
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Rela...MoreRituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Refractory/Relapsed Indolent N...MoreRefractory/Relapsed Indolent Non-Hodgkin Lymphoma
Active not recruiting
Phase Ⅰ
NCT01299857
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by R...MoreLong-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
Pemphigus
Completed
Phase Ⅲ
NCT01471067
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Blood And Marrow Transplantati...MoreBlood And Marrow Transplantation/Leukemia/Lymphoma/Transplantation Infection/Transplantation, Bone Marrow
Recruiting
Phase Ⅰ
NCT01399372
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Wit...MoreRituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Chemotherapeutic Agent Toxicit...MoreChemotherapeutic Agent Toxicity/Cognitive/Functional Effects/Lymphoma/Neurotoxicity/Radiation Toxicity
Active not recruiting
Phase Ⅱ
NCT01473628
Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follic...MoreRandomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II
Lymphoma
Recruiting
N/A
NCT01371630
Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)
Leukemia/Acute Lymphoblastic L...MoreLeukemia/Acute Lymphoblastic Leukemia
Recruiting
Phase Ⅰ/Ⅱ
NCT01567475
The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas
Non-Hodgkin's Lymphomas
Completed
Phase Ⅰ
NCT01562977
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL
Aggressive Lymphoma/Diffuse La...MoreAggressive Lymphoma/Diffuse Large B-cell Lymphoma/Mantle Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01423539
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse La...MoreA Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
Diffuse Large B-Cell Lymphoma
Withdrawn
Phase Ⅱ
NCT01429610
Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Precursor Cell Lymphoblastic L...MorePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Recruiting
Phase Ⅱ
NCT01313611
BRIEF Bendamustine and Rituximab In Elderly Follicular
Follicular Lymphoma
Terminated
Phase Ⅱ
NCT01400685
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma/B Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅰ
NCT01290120
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-H...MoreChemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
Burkitt Lymphoma/B-ALL
Completed
Phase Ⅱ
NCT01316523
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Non Hodgkin's Lymphoma
Recruiting
Phase Ⅱ
NCT01479842
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Extranodal Marginal Zone B-cel...MoreExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Splenic Marginal Zone Lymphoma/Waldenstrom Macroglobulinemia
Active not recruiting
Phase Ⅰ
NCT01445535
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
T-Cell Peripheral Lymphoma/Gam...MoreT-Cell Peripheral Lymphoma/Gamma Delta Hepatosplenic T-Cell Lymphoma/Subcutaneous Panniculitis-Like T-Cell Lymphoma/NK T-Cell Lymphoma
Active not recruiting
Phase Ⅰ
NCT01369849
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed C...MoreAkt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia/R...MoreChronic Lymphocytic Leukemia/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01358253
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Completed
Phase Ⅳ
NCT01359592
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT01497275
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Terminated
Phase Ⅱ
NCT01446900
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small L...MoreR-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukaemia/...MoreChronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
Terminated
Phase Ⅱ
NCT01456351
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
Non-Hodgkin's Lymphoma/Mantle ...MoreNon-Hodgkin's Lymphoma/Mantle Cell Lymphoma
Completed
Phase Ⅲ
NCT01345708
A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimm...MoreA Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Disease (...MoreAutoimmune Hemolytic Disease (Cold Type) (Warm Type)
Completed
Phase Ⅱ
NCT01271010
A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients Wit...MoreA Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status
Lymphocytic Leukemia, Chronic
Active not recruiting
Phase Ⅳ
NCT01279616
A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell...MoreA Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
Sickle Cell Disease
Suspended
Phase Ⅱ
NCT01373229
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Leukemia, Lymphocytic, Chronic...MoreLeukemia, Lymphocytic, Chronic, B-Cell
Completed
Phase Ⅰ
NCT01478542
OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab O...MoreOPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
CD20+ Aggressive B-Cell Lympho...MoreCD20+ Aggressive B-Cell Lymphoma
Recruiting
Phase Ⅲ
NCT01449344
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Re...MoreEfficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
Mantle Cell Lymphoma
Recruiting
Phase Ⅲ
NCT01458548
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
Post-transplantation Lymphopro...MorePost-transplantation Lymphoproliferative Disorder
Terminated
Phase Ⅱ
NCT01412879
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidatio...MoreS1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
Lymphoma
Terminated
Phase Ⅱ
NCT01338103
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
Pemphigus
Recruiting
N/A
NCT01295151
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking...MoreSWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
Rheumatoid Arthritis
Active not recruiting
Phase Ⅳ
NCT01381692
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untr...MoreBortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Cognitive Side Effects of Canc...MoreCognitive Side Effects of Cancer Therapy/Fatigue/Neurotoxicity Syndrome/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Small Lymphocytic Lymphoma/Therapy-Related Toxicity/Waldenstrom Macroglobulinemia
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01446133
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma...MoreCombination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
Leukemia/Lymphoma
Active not recruiting
Phase Ⅱ
NCT01421667
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Lymphoma, B-Cell/Lymphoma, Lar...MoreLymphoma, B-Cell/Lymphoma, Large B-Cell, Diffuse/Lymphoma, Non-Hodgkin/Lymphoma, T-Cell
Completed
Phase Ⅱ
NCT01370772
Intensified Rituimab Prephase Before FCR in Untreated B-CLL
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia CLL
Completed
Phase Ⅱ
NCT01148446
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL
Elderly Patients (>65 Years)/D...MoreElderly Patients (>65 Years)/Diffuse Large B Cell Lymphoma (DLBCL)
Completed
Phase Ⅲ
NCT01116232
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patie...MoreSirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Chronic Myeloproliferative Dis...MoreChronic Myeloproliferative Disorders/Graft Versus Host Disease/Leukemia/Lymphoma/Lymphoproliferative Disorder/Multiple Myeloma and Plasma Cell Neoplasm/Myelodysplastic Syndromes/Myelodysplastic/Myeloproliferative Neoplasms
Terminated
Phase Ⅱ
NCT01088724
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lympho...MoreFludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
Post-transplant Lymphoprolifer...MorePost-transplant Lymphoproliferative Disease (PTLD)/Non Burkitt
Completed
Phase Ⅳ
NCT01133158
R-BMD GELTAMO Relapsed Lymphoma
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅱ
NCT01153971
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B...MoreA Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT01118845
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell ...MoreStudy of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma/Lymphom...MoreNon-Hodgkin's Lymphoma/Lymphoma, Large Cell/Diffuse, Mantle Cell Lymphoma, Lymphoma/Follicular Lymphoma/Large B-Cell, Diffuse
Completed
Phase Ⅱ
NCT01269385
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leuk...MoreImprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia/Refractory Chronic Lymphocytic Leukemia/Stage 0 Chronic Lymphocytic Leukemia/Stage I Chronic Lymphocytic Leukemia/Stage II Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01087151
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, ...MoreA Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT01078974
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Active not recruiting
Phase Ⅰ
NCT01085617
Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagno...MoreStandard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Leukemia/Mucositis/Oral Compli...MoreLeukemia/Mucositis/Oral Complications
Recruiting
Phase Ⅲ
NCT01226849
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse L...MoreFeasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Active not recruiting
Phase Ⅰ
NCT01054781
Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or ...MoreIntensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma ...MoreDiffuse Large B-cell Lymphoma (DLBCL)
Completed
Phase Ⅱ
NCT01161628
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Chronic Graft-versus-host Dise...MoreChronic Graft-versus-host Disease
Completed
Phase Ⅱ
NCT01268033
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome Durin...MoreEfficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
Childhood Idiopathic Nephrotic...MoreChildhood Idiopathic Nephrotic Syndrome
Completed
Phase Ⅱ/Ⅲ
NCT01234467
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma/...MoreDiffuse Large B-Cell Lymphoma/Lymphoma, Diffuse Large-Cell/Diffuse Large-Cell Lymphoma/Lymphoma
Active not recruiting
Phase Ⅱ
NCT01165112
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed...MoreBendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
Recurrent Adult Diffuse Large ...MoreRecurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Hodgkin Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01047072
Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe System...MoreLow-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
Systemic Scleroderma
Withdrawn
Phase Ⅱ
NCT01144364
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma...MoreA Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkin's Lymphoma
Completed
Phase Ⅲ
NCT01238692
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma ...MoreA Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Diffuse Large B Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT01042509
Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Diseas...MoreCombination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
Graft vs Host Disease
Recruiting
N/A
NCT01066598
A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host...MoreA Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)
Graft Versus Host Disease
Terminated
Phase Ⅱ
NCT01144403
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untre...MoreA Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
Diffuse Large B-Cell Lymphoma
Terminated
Phase Ⅱ
NCT01206777
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignanc...MoreFeasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
Indolent or Intermediate Grade...MoreIndolent or Intermediate Grade B-cell Malignancy
Completed
Phase Ⅱ
NCT01045928
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymph...MoreLenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Adult Non-Hodgkin Lymphoma/Adu...MoreAdult Non-Hodgkin Lymphoma/Adult Grade III Lymphomatoid Granulomatosis/Contiguous Stage II Adult Burkitt Lymphoma/Contiguous Stage II Adult Diffuse Large Cell Lymphoma/Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma/Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma/Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma/Contiguous Stage II Adult Lymphoblastic Lymphoma/Contiguous Stage II Grade 1 Follicular Lymphoma/Contiguous Stage II Grade 2 Follicular Lymphoma/Contiguous Stage II Grade 3 Follicular Lymphoma/Contiguous Stage II Mantle Cell Lymphoma/Contiguous Stage II Marginal Zone Lymphoma/Contiguous Stage II Small Lymphocytic Lymphoma/Cutaneous B-cell Non-Hodgkin Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Adult Burkitt Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma/Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma/Noncontiguous Stage II Adult Lymphoblastic Lymphoma/Noncontiguous Stage II Grade 1 Follicular Lymphoma/Noncontiguous Stage II Grade 2 Follicular Lymphoma/Noncontiguous Stage II Grade 3 Follicular Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Noncontiguous Stage II Marginal Zone Lymphoma/Noncontiguous Stage II Small Lymphocytic Lymphoma/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Small Lymphocytic Lymphoma/Splenic Marginal Zone Lymphoma/Stage I Adult Burkitt Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage I Adult Diffuse Mixed Cell Lymphoma/Stage I Adult Diffuse Small Cleaved Cell Lymphoma/Stage I Adult Immunoblastic Large Cell Lymphoma/Stage I Adult Lymphoblastic Lymphoma/Stage I Grade 1 Follicular Lymphoma/Stage I Grade 2 Follicular Lymphoma/Stage I Grade 3 Follicular Lymphoma/Stage I Mantle Cell Lymphoma/Stage I Marginal Zone Lymphoma/Stage I Small Lymphocytic Lymphoma/Stage III Adult Burkitt Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Mixed Cell Lymphoma/Stage III Adult Diffuse Small Cleaved Cell Lymphoma/Stage III Adult Immunoblastic Large Cell Lymphoma/Stage III Adult Lymphoblastic Lymphoma/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage III Mantle Cell Lymphoma/Stage III Marginal Zone Lymphoma/Stage III Small Lymphocytic Lymphoma/Stage IV Adult Burkitt Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Mixed Cell Lymphoma/Stage IV Adult Diffuse Small Cleaved Cell Lymphoma/Stage IV Adult Immunoblastic Large Cell Lymphoma/Stage IV Adult Lymphoblastic Lymphoma/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Grade 3 Follicular Lymphoma/Stage IV Mantle Cell Lymphoma/Stage IV Marginal Zone Lymphoma/Stage IV Small Lymphocytic Lymphoma/Waldenstrom Macroglobulinemia
Terminated
Phase Ⅰ
NCT01267812
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergon...MoreBortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Contiguous Stage II Mantle Cel...MoreContiguous Stage II Mantle Cell Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Recurrent Mantle Cell Lymphoma/Stage I Mantle Cell Lymphoma/Stage III Mantle Cell Lymphoma/Stage IV Mantle Cell Lymphoma
Recruiting
Phase Ⅱ
NCT01173679
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CL...MoreDasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Terminated
Phase Ⅱ
NCT01209130
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapse...MoreA Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma, Chroni...MoreNon-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Completed
Phase Ⅰ
NCT01164098
Rituximab to Prevent Recurrence of Proteinuria
FSGS/Proteinuria
Suspended
Phase Ⅲ
NCT01280682
Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
Diabetes Mellitus, Type 1
Recruiting
Phase Ⅳ
NCT01096992
Fludarabine, Bendamustine, and Rituximab (FBR) in Chronic Lymphocytic Leukemia (CLL)
Leukemia
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01055496
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin...MoreStudy Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Lymphoma, B-Cell
Completed
Phase Ⅰ
NCT01181999
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Di...MoreRituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
Lymphoma, Large B-cell, Diffus...MoreLymphoma, Large B-cell, Diffuse
Recruiting
Phase Ⅱ
NCT01181258
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Mal...MorePenostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
Non-Hodgkin Lymphoma/Chronic L...MoreNon-Hodgkin Lymphoma/Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT01203930
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Chronic Lymphocytic Leukemia (...MoreChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Terminated
Phase Ⅱ
NCT01145495
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or St...MoreLenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Stage II Grade 1 Contiguous Fo...MoreStage II Grade 1 Contiguous Follicular Lymphoma/Stage II Grade 1 Non-Contiguous Follicular Lymphoma/Stage II Grade 2 Contiguous Follicular Lymphoma/Stage II Grade 2 Non-Contiguous Follicular Lymphoma/Stage II Grade 3 Contiguous Follicular Lymphoma/Stage II Grade 3 Non-Contiguous Follicular Lymphoma/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Grade 3 Follicular Lymphoma
Active not recruiting
Phase Ⅱ
NCT01213095
Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)
Lymphoma
Completed
Phase Ⅱ
NCT01156909
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
Chronic Fatigue Syndrome/Myalg...MoreChronic Fatigue Syndrome/Myalgic Encephalomyelitis
Completed
Phase Ⅱ
NCT01076556
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lympho...MoreCyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia/P...MoreChronic Lymphocytic Leukemia/Prolymphocytic Leukemia/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Stage I Chronic Lymphocytic Leukemia/Stage I Small Lymphocytic Lymphoma/Stage II Chronic Lymphocytic Leukemia/Stage II Small Lymphocytic Lymphoma/Stage III Chronic Lymphocytic Leukemia/Stage III Small Lymphocytic Lymphoma/Stage IV Chronic Lymphocytic Leukemia/Stage IV Small Lymphocytic Lymphoma
Terminated
Phase Ⅰ
NCT01156922
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Sy...MoreB-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
Chronic Fatigue Syndrome/Myalg...MoreChronic Fatigue Syndrome/Myalgic Encephalomyelitis
Terminated
Phase Ⅱ
NCT01180036
MEmbranous Nephropathy Trial Of Rituximab
Idiopathic Membranous Nephropa...MoreIdiopathic Membranous Nephropathy
Active not recruiting
Phase Ⅱ/Ⅲ
NCT01097057
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With No...MoreRituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Non-Hodgkin Lymphoma
Active not recruiting
Phase Ⅱ
NCT01135641
Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclospor...MoreStudy of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)
Graft Versus Host Disease
Completed
Phase Ⅱ
NCT01125176
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Pat...MoreAlternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
Chronic Lymphocytic Leukemia
Recruiting
Phase Ⅱ
NCT01197560
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lym...MoreStudy of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Active not recruiting
Phase Ⅱ/Ⅲ
NCT01044745
Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Tra...MoreRituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Accelerated Phase Chronic Myel...MoreAccelerated Phase Chronic Myelogenous Leukemia/Adult Acute Lymphoblastic Leukemia in Remission/Adult Acute Myeloid Leukemia in Remission/Adult Nasal Type Extranodal NK/T-cell Lymphoma/Blastic Phase Chronic Myelogenous Leukemia/Contiguous Stage II Adult Burkitt Lymphoma/Contiguous Stage II Adult Diffuse Large Cell Lymphoma/Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma/Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma/Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma/Contiguous Stage II Adult Lymphoblastic Lymphoma/Contiguous Stage II Grade 1 Follicular Lymphoma/Contiguous Stage II Grade 2 Follicular Lymphoma/Contiguous Stage II Grade 3 Follicular Lymphoma/Contiguous Stage II Mantle Cell Lymphoma/Contiguous Stage II Marginal Zone Lymphoma/Contiguous Stage II Small Lymphocytic Lymphoma/de Novo Myelodysplastic Syndromes/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Graft Versus Host Disease/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Adult Burkitt Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma/Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma/Noncontiguous Stage II Adult Lymphoblastic Lymphoma/Noncontiguous Stage II Grade 1 Follicular Lymphoma/Noncontiguous Stage II Grade 2 Follicular Lymphoma/Noncontiguous Stage II Grade 3 Follicular Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Noncontiguous Stage II Marginal Zone Lymphoma/Noncontiguous Stage II Small Lymphocytic Lymphoma/Previously Treated Myelodysplastic Syndromes/Recurrent Adult Acute Lymphoblastic Leukemia/Recurrent Adult Acute Myeloid Leukemia/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Adult T-cell Leukemia/Lymphoma/Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Mycosis Fungoides/Sezary Syndrome/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Relapsing Chronic Myelogenous Leukemia/Secondary Myelodysplastic Syndromes/Splenic Marginal Zone Lymphoma/Stage I Adult Burkitt Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage I Adult Diffuse Mixed Cell Lymphoma/Stage I Adult Diffuse Small Cleaved Cell Lymphoma/Stage I Adult Immunoblastic Large Cell Lymphoma/Stage I Adult Lymphoblastic Lymphoma/Stage I Adult T-cell Leukemia/Lymphoma/Stage I Chronic Lymphocytic Leukemia/Stage I Cutaneous T-cell Non-Hodgkin Lymphoma/Stage I Grade 1 Follicular Lymphoma/Stage I Grade 2 Follicular Lymphoma/Stage I Grade 3 Follicular Lymphoma/Stage I Mantle Cell Lymphoma/Stage I Marginal Zone Lymphoma/Stage I Mycosis Fungoides/Sezary Syndrome/Stage I Small Lymphocytic Lymphoma/Stage II Adult T-cell Leukemia/Lymphoma/Stage II Chronic Lymphocytic Leukemia/Stage II Cutaneous T-cell Non-Hodgkin Lymphoma/Stage II Mycosis Fungoides/Sezary Syndrome/Stage III Adult Burkitt Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Mixed Cell Lymphoma/Stage III Adult Diffuse Small Cleaved Cell Lymphoma/Stage III Adult Immunoblastic Large Cell Lymphoma/Stage III Adult Lymphoblastic Lymphoma/Stage III Adult T-cell Leukemia/Lymphoma/Stage III Chronic Lymphocytic Leukemia/Stage III Cutaneous T-cell Non-Hodgkin Lymphoma/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage III Mantle Cell Lymphoma/Stage III Marginal Zone Lymphoma/Stage III Mycosis Fungoides/Sezary Syndrome/Stage III Small Lymphocytic Lymphoma/Stage IV Adult Burkitt Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Mixed Cell Lymphoma/Stage IV Adult Diffuse Small Cleaved Cell Lymphoma/Stage IV Adult Immunoblastic Large Cell Lymphoma/Stage IV Adult Lymphoblastic Lymphoma/Stage IV Adult T-cell Leukemia/Lymphoma/Stage IV Chronic Lymphocytic Leukemia/Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Grade 3 Follicular Lymphoma/Stage IV Mantle Cell Lymphoma/Stage IV Marginal Zone Lymphoma/Stage IV Mycosis Fungoides/Sezary Syndrome/Stage IV Small Lymphocytic Lymphoma/Untreated Adult Acute Lymphoblastic Leukemia/Untreated Adult Acute Myeloid Leukemia/Waldenström Macroglobulinemia
Active not recruiting
Phase Ⅱ
NCT01095172
RituxiMab INDuction in Renal Transplantation
Function of Renal Transplant
Recruiting
Phase Ⅳ
NCT01234766
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular ...MoreBendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Lymphoma, Follicular
Active not recruiting
Phase Ⅱ
NCT01107951
Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
Immune Thrombocytopenic Purpur...MoreImmune Thrombocytopenic Purpura
Completed
Phase Ⅱ
NCT01830465
VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma
Non Hodgkin's Follicular Lymph...MoreNon Hodgkin's Follicular Lymphoma
Completed
Phase Ⅱ
NCT01181154
Rituximab in Auto-Immune Hemolytic Anemia
Warm Autoimmune Hemolytic Anem...MoreWarm Autoimmune Hemolytic Anemia
Active not recruiting
Phase Ⅲ
NCT01244958
Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT01056510
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leuke...MoreA Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
Lymphocytic Leukemia, Chronic
Completed
Phase Ⅳ
NCT01126541
SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis...MoreSMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT01199575
Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemi...MoreMulti-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia/C...MoreChronic Lymphocytic Leukemia/CLL
Active not recruiting
Phase Ⅱ
NCT01088048
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents...MoreStudy to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Indolent Non-Hodgkin's Lymphom...MoreIndolent Non-Hodgkin's Lymphoma/Chronic Lymphocytic Leukemia/Mantle Cell Lymphoma
Completed
Phase Ⅰ
NCT01058239
Bortezomib Plus Rituximab for EBV+ PTLD
Post-transplant Lymphoprolifer...MorePost-transplant Lymphoproliferative Disease/Solid Organ Transplant/Stem Cell Transplant (Bone Marrow Transplant)/Epstein Barr Virus Infections
Active not recruiting
Phase Ⅱ
NCT01127841
Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed A...MoreTrial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line
Follicular Non-Hodgking´s Lymp...MoreFollicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.
Active not recruiting
Phase Ⅱ
NCT01253460
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocyt...MoreSapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Leukemia
Recruiting
Phase Ⅱ
NCT01086631
Rituximab for Autoimmune Retinopathy
Autoimmune Disease
Completed
Phase Ⅰ
NCT01230788
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
Leukemia/Acute Lymphoblastic L...MoreLeukemia/Acute Lymphoblastic Leukemia/ALL
Terminated
N/A
NCT01118234
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphoc...MoreRituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅲ
NCT01136395
Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Tra...MoreImpact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
Kidney Transplantation/Rituxim...MoreKidney Transplantation/Rituximab/Living Donors/Immunology/Virus
Active not recruiting
Phase Ⅱ
NCT01266317
Combined PEX, Rituximab and Steroids in Acute IPF Exacerbations
IPF
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01078142
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Follicular Lymphoma/Mantle Cel...MoreFollicular Lymphoma/Mantle Cell Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01232556
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymph...MoreA Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Lymphoma, Non-Hodgkin
Terminated
Phase Ⅲ
NCT01117662
Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
Acute Rejection
Active not recruiting
Phase Ⅲ
NCT01134575
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Active not recruiting
Phase Ⅰ
NCT01117129
A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magn...MoreA Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)
Rheumatoid Arthritis
Terminated
Phase Ⅳ
NCT01193842
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse...MoreVorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
AIDS-Related Diffuse Large Cel...MoreAIDS-Related Diffuse Large Cell Lymphoma/AIDS-Related Plasmablastic Lymphoma/AIDS-Related Primary Effusion Lymphoma/Grade 3b Follicular Lymphoma/HIV Infection/Plasmablastic Lymphoma/Primary Effusion Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage I Grade 3 Follicular Lymphoma/Stage II Contiguous Adult Diffuse Large Cell Lymphoma/Stage II Grade 3 Contiguous Follicular Lymphoma/Stage II Grade 3 Non-Contiguous Follicular Lymphoma/Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma/Stage IV Grade 3 Follicular Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT01103388
Rituximab Maintenance After Autologous Transplantation
Non-Hodgkin's Lymphoma
Terminated
Phase Ⅲ
NCT01125293
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglob...MoreEverolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01046006
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macrogl...MoreBortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Active not recruiting
Phase Ⅱ
NCT01216683
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Wi...MoreBendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT01059786
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed...MoreRandomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Hairy Cell Leukemia
Recruiting
Phase Ⅱ
NCT01238146
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or ...MoreObatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cel...MoreExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Splenic Marginal Zone Lymphoma
Withdrawn
Phase Ⅰ/Ⅱ
NCT01073163
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interv...MoreStudy to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Non-Hodgkin's Lymphoma/Mantle ...MoreNon-Hodgkin's Lymphoma/Mantle Cell Lymphoma
Completed
Phase Ⅲ
NCT01263704
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Prim...MoreA Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Active not recruiting
Phase Ⅱ
NCT01212094
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Pat...MoreDouble Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Multiple Sclerosis
Terminated
Phase Ⅰ/Ⅱ
NCT01082939
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic ...MoreCyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT01186458
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Terminated
Phase Ⅱ
NCT01279902
Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL
Diffuse Large B-cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT00824135
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditio...MoreHaploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
Hematologic Malignancies
Active not recruiting
Phase Ⅰ
NCT01021735
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT01005979
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/R...MoreA Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Leukemia, Lymphocytic, Chronic...MoreLeukemia, Lymphocytic, Chronic, B-Cell/Chronic Lymphocytic Leukemia/Lymphoma, Small Lymphocytic
Terminated
Phase Ⅰ
NCT00869999
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Diffuse Large B-cell Lymphoma
Completed
Phase Ⅱ
NCT01010217
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Blood Stem Cell Transplant Fai...MoreBlood Stem Cell Transplant Failure/Leukemia/Hematologic Malignancies
Active not recruiting
Phase Ⅱ
NCT00930514
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Ly...MoreA Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
Lymphoma, Follicular
Completed
Phase Ⅰ
NCT00983619
A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malign...MoreA Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
B-cell Malignancies
Active not recruiting
Phase Ⅰ
NCT00974792
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Ly...MoreCombination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT00851552
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Larg...MoreBortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Lymphoma
Terminated
Phase Ⅱ
NCT00987493
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell ...MoreRituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00877006
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Li...MoreStudy of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Non-Hodgkin's Lymphoma/Mantle ...MoreNon-Hodgkin's Lymphoma/Mantle Cell Lymphoma
Active not recruiting
Phase Ⅲ
NCT00992030
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
Hodgkin Lymphoma
Active not recruiting
Phase Ⅲ
NCT01032122
Rituximab in Metastatic Melanoma
Metastatic Melanoma
Terminated
Phase Ⅰ
NCT00986947
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
Kidney Failure
Completed
Phase Ⅱ
NCT00848692
Drug Intervention in Chronic Fatigue Syndrome
Chronic Fatigue Syndrome
Completed
Phase Ⅱ/Ⅲ
NCT01001780
Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-V...MorePentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease
Active Chronic Graft Versus Ho...MoreActive Chronic Graft Versus Host Disease
Withdrawn
Phase Ⅱ
NCT00939328
S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That ...MoreS0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
Leukemia
Withdrawn
Phase Ⅱ
NCT01027000
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small...MoreDonor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia/Lymphoma
Active not recruiting
Phase Ⅱ
NCT00845104
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocyt...MoreFludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia/Refractory Chronic Lymphocytic Leukemia
Withdrawn
Phase Ⅱ
NCT00831597
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell L...MoreBendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Completed
Phase Ⅱ
NCT00867087
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin'...MoreStudy Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma, B-Cell
Completed
Phase Ⅱ
NCT00981838
Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS...MoreRituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)
Nephrotic Syndrome
Completed
Phase Ⅲ
NCT01010061
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Unt...MoreCLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
Lymphocytic Leukemia, Chronic
Active not recruiting
Phase Ⅲ
NCT00940342
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
Leukemia
Active not recruiting
Phase Ⅱ
NCT00949988
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00845832
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActe...MoreA Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
Rheumatoid Arthritis
Terminated
Phase Ⅱ
NCT00927797
Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-L...MoreInterventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)
Immunocytoma/Morbus Waldenströ...MoreImmunocytoma/Morbus Waldenström/B-Cell Non-Hodgkin's Lymphoma/B-Cell Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅱ
NCT00968331
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/...MoreStudy of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Terminated
Phase Ⅱ
NCT01124526
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st...MoreEfficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
Non Hodgkin Lymphoma
Completed
Phase Ⅳ
NCT00989352
Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With ...MoreMethotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma
Primary Non Hodgkin Lymphoma o...MorePrimary Non Hodgkin Lymphoma of the Central Nervous System
Recruiting
Phase Ⅱ
NCT00820469
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
Renal Transplant/Autoimmune Di...MoreRenal Transplant/Autoimmune Diseases
Completed
Phase Ⅳ
NCT00983944
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With P...MoreRituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Lymphoma
Withdrawn
Phase Ⅱ
NCT00856245
Evaluate Rituximab in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicu...MoreEvaluate Rituximab in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Non-Hodgkins Lymphoma
Active not recruiting
Phase Ⅱ
NCT00980395
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Ind...MoreBortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Lymphoma/Mantle Cell Lymphoma/...MoreLymphoma/Mantle Cell Lymphoma/Indolent Lymphoma/SLL
Active not recruiting
Phase Ⅱ
NCT01185262
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lym...MoreActivity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Completed
Phase Ⅰ
NCT00850499
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular ...MorePhase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Follicular Lymphoma
Terminated
Phase Ⅱ
NCT00958256
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Mantle Cell Lymphoma/Lymphoma
Completed
Phase Ⅱ
NCT01300793
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
Non-Hodgkin's Lymphoma/B-cell ...MoreNon-Hodgkin's Lymphoma/B-cell Lymphoma
Terminated
Phase Ⅰ
NCT00901069
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
Lymphoma/Hodgkin Disease/Lymph...MoreLymphoma/Hodgkin Disease/Lymphoma, Non-Hodgkin
Active not recruiting
Phase Ⅰ
NCT00954005
Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
Indolent Lymphoma
Terminated
Phase Ⅰ/Ⅱ
NCT00892827
Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refra...MoreCombined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia
Advanced Refractory Chronic Ly...MoreAdvanced Refractory Chronic Lymphocytic Leukemia
Recruiting
Phase Ⅱ
NCT01040871
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rit...MoreStudy of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Completed
Phase Ⅱ
NCT00992134
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymp...MoreImmunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Completed
Phase Ⅱ
NCT00891839
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle...MoreBendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT01030900
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed o...MorePhase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Hodgkin Lymphoma/Diffuse Large...MoreHodgkin Lymphoma/Diffuse Large B-Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT00908583
Desensitization in Kidney Transplantation
HLA Sensitization
Completed
Phase Ⅳ
NCT01004991
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT00878254
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Ly...MoreRituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT00832234
Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
Waldenstroms Macroglobulinemia
Completed
Phase Ⅱ
NCT00880815
Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies
Leukemia/Lymphoma
Completed
Phase Ⅰ
NCT00833534
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Sma...MoreLenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
Leukemia/Lymphoma
Withdrawn
Phase Ⅱ
NCT00855205
Rituximab for Pulmonary Sarcoidosis
Sarcoidosis
Completed
Phase Ⅱ
NCT00965289
High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
B-Cell Lymphoma
Completed
Phase Ⅱ
NCT00974233
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refracto...MoreStudy of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Completed
Phase Ⅱ
NCT00963534
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantl...MoreLenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Mantle Cell Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00841945
Treatment of Aggressive Localized Lymphoma
B Cell Lymphoma
Terminated
Phase Ⅲ
NCT00971763
Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Tre...MoreGemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00905034
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic ...MoreMethotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
Leukemia, Lymphocytic, Acute
Completed
Phase Ⅱ
NCT00907751
Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Pu...MoreThrombotic Thrombocytopenic Purpura
Completed
Phase Ⅱ
NCT00918723
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previou...MoreVorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Stage I Chronic Lymphocytic Leukemia/Stage I Small Lymphocytic Lymphoma/Stage II Chronic Lymphocytic Leukemia/Stage II Small Lymphocytic Lymphoma/Stage III Chronic Lymphocytic Leukemia/Stage III Small Lymphocytic Lymphoma/Stage IV Chronic Lymphocytic Leukemia/Stage IV Small Lymphocytic Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT01000610
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to ...MoreA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT00904722
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lympho...MoreMonoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00881387
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed...MoreRituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
Lymphoma
Withdrawn
Phase Ⅱ
NCT01000441
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rheumatoid Arthritis
Recruiting
Phase Ⅳ
NCT01015248
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associa...MoreTrial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
MALT LYMPHOMA
Completed
Phase Ⅱ
NCT00921414
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
Mantle Cell Lymphoma
Completed
Phase Ⅲ
NCT00901927
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lym...MoreBendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
Follicular Lymphoma
Terminated
Phase Ⅱ
NCT01011920
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Central Nervous System Lymphom...MoreCentral Nervous System Lymphoma
Active not recruiting
Phase Ⅱ
NCT00829205
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients ...MoreSe-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Lymphoma
Withdrawn
Phase Ⅰ/Ⅱ
NCT01014208
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant i...MoreOfatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Lymphoma, Large-Cell, Diffuse
Completed
Phase Ⅲ
NCT00911183
Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulat...MoreRituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT00945724
This Trial is a Safety and Feasibility Study of Combination of State of the Art Chemoimmunotherapy, ...MoreThis Trial is a Safety and Feasibility Study of Combination of State of the Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Testicular Diffuse Large B-cell Lymphoma
Primary Testicular Diffuse Lar...MorePrimary Testicular Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT00972101
Infusion of Expanded Cord Blood T Cells
Stem Cell Transplantation/Leuk...MoreStem Cell Transplantation/Leukemia/Lymphoma/Pediatric Disorders
Withdrawn
Phase Ⅰ
NCT00909077
The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Di...MoreThe Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Pu...MoreIdiopathic Thrombocytopenic Purpura
Active not recruiting
Phase Ⅲ
NCT00895661
High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
B-cell Lymphoma/Indolent B-cel...MoreB-cell Lymphoma/Indolent B-cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT01007292
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Trea...MoreA Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT00848328
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT01029730
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lym...MoreTrial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00869323
Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
Lymphoproliferative Disorder
Terminated
Phase Ⅱ
NCT00977977
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Nephrotic Syndrome/Proteinuria...MoreNephrotic Syndrome/Proteinuria/Autoimmune Disease/Glomerular Disease/Membranous Glomerulonephritis
Recruiting
Phase Ⅱ
NCT00934648
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Res...MoreA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT00818961
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Leukemia/Lymphoma/Myelodysplas...MoreLeukemia/Lymphoma/Myelodysplastic Syndromes/Myelodysplastic/Myeloproliferative Diseases
Terminated
Phase Ⅱ
NCT00899431
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅱ
NCT00908986
Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
Lupus Nephritis
Withdrawn
N/A
NCT00980304
R Retreatment in 1st Relapsed DLBCL
Lymphomas
Not yet recruiting
Phase Ⅱ
NCT00937131
The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Pu...MoreThrombotic Thrombocytopenic Purpura (TTP)
Active not recruiting
Phase Ⅱ
NCT00963703
Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
N/A
NCT00860457
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT01035463
Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Ste...MoreLenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy
Adult Nasal Type Extranodal NK...MoreAdult Nasal Type Extranodal NK/T-cell Lymphoma/Anaplastic Large Cell Lymphoma/Angioimmunoblastic T-cell Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Peripheral T-cell Lymphoma/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Mycosis Fungoides/Sezary Syndrome/Recurrent Small Lymphocytic Lymphoma/Splenic Marginal Zone Lymphoma/Stage III Adult Burkitt Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Mixed Cell Lymphoma/Stage III Adult Diffuse Small Cleaved Cell Lymphoma/Stage III Adult Immunoblastic Large Cell Lymphoma/Stage III Adult Lymphoblastic Lymphoma/Stage III Cutaneous T-cell Non-Hodgkin Lymphoma/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage III Mantle Cell Lymphoma/Stage III Marginal Zone Lymphoma/Stage III Mycosis Fungoides/Sezary Syndrome/Stage III Small Lymphocytic Lymphoma/Stage IV Adult Burkitt Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Mixed Cell Lymphoma/Stage IV Adult Diffuse Small Cleaved Cell Lymphoma/Stage IV Adult Immunoblastic Large Cell Lymphoma/Stage IV Adult Lymphoblastic Lymphoma/Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Grade 3 Follicular Lymphoma/Stage IV Mantle Cell Lymphoma/Stage IV Marginal Zone Lymphoma/Stage IV Mycosis Fungoides/Sezary Syndrome/Stage IV Small Lymphocytic Lymphoma/Waldenström Macroglobulinemia
Recruiting
Phase Ⅰ/Ⅱ
NCT00992446
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating P...MoreBortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Adult Diffuse Large B-Cell Lym...MoreAdult Diffuse Large B-Cell Lymphoma/B-Cell Non-Hodgkin Lymphoma/Follicular Lymphoma/Mantle Cell Lymphoma/Non-Hodgkin Lymphoma/T-Cell Non-Hodgkin Lymphoma
Active not recruiting
Phase Ⅱ
NCT00923013
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Hairy Cell Leukemia
Recruiting
Phase Ⅱ
NCT00877214
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Follicular Lymphomas/Immunocyt...MoreFollicular Lymphomas/Immunocytomas/Marginal Zone Lymphomas/Mantle-Cell Lymphomas/Lymphocytic Lymphoma/Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅲ
NCT00842595
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
Diffuse Large B-Cell Lymphoma
Completed
Phase Ⅱ
NCT00936546
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, E...MoreA Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
Debilitating Fibrosing Skin Di...MoreDebilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)
Active not recruiting
Phase Ⅱ
NCT01009970
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R...MoreStudy With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT00972478
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage ...MoreVorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Stage II Contiguous Adult Diff...MoreStage II Contiguous Adult Diffuse Large Cell Lymphoma/Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00863369
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00849355
Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patie...MoreCiclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk
No Hodgkin B Lymphoma
Recruiting
Phase Ⅱ
NCT00896519
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advan...MoreGM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
Lymphoma
Not yet recruiting
Phase Ⅱ
NCT00799773
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopen...MoreEvaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Pu...MoreThrombotic Thrombocytopenic Purpura
Terminated
Phase Ⅲ
NCT00801632
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation/Kidney ...MoreKidney Transplantation/Kidney Failure, Chronic
Completed
Phase Ⅱ
NCT00812669
CLL-Irl Study. ICORG 07-01, V7
Leukemia
Active not recruiting
Phase Ⅱ
NCT00807196
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lym...MoreZevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Non-Hodgkins Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT00794638
A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patient...MoreA Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma/Diffuse...MoreNon-Hodgkin's Lymphoma/Diffuse Large B-cell Lymphoma/Mantle Cell Lymphoma/Follicular Lymphoma
Completed
Phase Ⅰ
NCT00816595
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B...MorePentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia/Lymphoma
Active not recruiting
Phase Ⅱ
NCT00794820
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00797810
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's...MoreIntensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
Acute Lymphoblastic Leukemia/N...MoreAcute Lymphoblastic Leukemia/Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅳ
NCT00798785
Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients
Diabetes Mellitus, Type 1
Recruiting
Phase Ⅰ/Ⅱ
NCT00801281
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
Follicular Lymphoma/Marginal Z...MoreFollicular Lymphoma/Marginal Zone Lymphoma/Small Lymphocytic Lymphoma/Lymphoplasmacytic Lymphoma
Active not recruiting
Phase Ⅲ
NCT00525876
Non-Myeloablative Allogeneic Stem Cell Transplantation
Lymphoma
Completed
N/A
NCT00577278
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melph...MoreYttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Graft Versus Host Disease/Leuk...MoreGraft Versus Host Disease/Leukemia/Lymphoma
Active not recruiting
Phase Ⅱ
NCT00636792
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects ...MoreA Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
Follicular Lymphoma
Completed
Phase Ⅱ
NCT00481832
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Active not recruiting
Phase Ⅱ
NCT00504491
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukaemia/...MoreChronic Lymphocytic Leukaemia/Patients Resistant to a Purine Analogous/Patients Relapsed With Purines Therapy
Withdrawn
Phase Ⅱ
NCT00749112
Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
Idiopathic Thrombocytopenic Pu...MoreIdiopathic Thrombocytopenic Purpura/Anemia, Hemolytic, Autoimmune
Completed
Phase Ⅱ/Ⅲ
NCT00636155
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lymphoma, Small Lymphocytic/Le...MoreLymphoma, Small Lymphocytic/Leukemia, Lymphocytic, Chronic
Terminated
Phase Ⅱ
NCT00581776
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Ly...MorePhase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT00695097
The Effect of Rituximab on the Development of Anti-Donor Antibodies
Renal Transplant Rejection
Completed
N/A
NCT00609869
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Ri...MoreLenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
Lymphocytic Leukemia/Mantle Ce...MoreLymphocytic Leukemia/Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT00544219
PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxo...MorePET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Lymphoma
Completed
N/A
NCT00476164
Study of Rituximab to Treat Chronic Renal Transplant Rejection
Kidney Transplantation/Graft R...MoreKidney Transplantation/Graft Rejection/Immunosuppression
Recruiting
Phase Ⅳ
NCT00641095
Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untr...MoreFludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅲ
NCT00556192
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Er...MoreCan Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Completed
Phase Ⅱ
NCT00422942
A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients Wi...MoreA Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Terminated
Phase Ⅱ
NCT00536978
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx f...MoreNatural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Lymphoma/Leukemia
Completed
Phase Ⅱ
NCT00758693
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With C...MoreFrontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Withdrawn
Phase Ⅱ
NCT00504751
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅱ
NCT00783367
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatmen...MoreCombination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Follicular Lymphoma/Marginal Z...MoreFollicular Lymphoma/Marginal Zone B-Cell Lymphoma/MALT Lymphoma/Lymphoma of Mucosa-Associated Lymphoid Tissue/Lymphoma, Small Lymphocytic/Waldenstrom Macroglobulinemia/Mantle-Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT00498368
Rituximab in Progressive IgA Nephropathy
IgA Nephropathy
Completed
Phase Ⅳ
NCT00422383
A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With R...MoreA Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT00510887
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Lymphoma, Follicular
Terminated
Phase Ⅱ
NCT00718549
A Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chron...MoreA Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Completed
Phase Ⅲ
NCT00555542
An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅱ
NCT00695786
Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00602459
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With...MoreFludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Stage I Chronic Lymphocytic Leukemia/Stage II Chronic Lymphocytic Leukemia/Stage III Chronic Lymphocytic Leukemia/Stage IV Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅱ
NCT00472420
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Man...MoreA Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT00691015
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patient...MoreSirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Chronic Myeloproliferative Dis...MoreChronic Myeloproliferative Disorders/Leukemia/Lymphoma/Multiple Myeloma and Plasma Cell Neoplasm/Myelodysplastic Syndromes/Myelodysplastic/Myeloproliferative Neoplasms
Active not recruiting
Phase Ⅱ
NCT00439556
Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00530179
FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Active not recruiting
N/A
NCT00664599
Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease
Behcet's Syndrome
Completed
Phase Ⅱ
NCT00654732
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma
Hodgkin Lymphoma
Active not recruiting
Phase Ⅱ
NCT00646750
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory La...MoreTransplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT00711828
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Ref...MoreRituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Extranodal Marginal Zone Lymph...MoreExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue/Nodal Marginal Zone Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Splenic Marginal Zone Lymphoma/Waldenstrom Macroglobulinemia
Active not recruiting
Phase Ⅱ
NCT00575406
Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diff...MoreMulticentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Completed
Phase Ⅱ
NCT00774202
Study of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine,...MoreStudy of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
Immune Thrombocytopenic Purpur...MoreImmune Thrombocytopenic Purpura
Completed
Phase Ⅱ/Ⅲ
NCT00690560
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With...MoreCombination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00667329
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
Lymphoma
Active not recruiting
N/A
NCT00667615
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for El...MoreTrial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Hodgkin's Disease/Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00436904
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leuke...MoreAlemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
Leukemia
Completed
Phase Ⅱ
NCT00546377
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphoc...MorePentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Leukemia/Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00435955
Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lympho...MoreComparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma
Follicular Lymphoma
Active not recruiting
Phase Ⅲ
NCT00472056
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancie...MoreRituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
Lymphoma
Completed
Phase Ⅱ
NCT00759603
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Completed
Phase Ⅱ
NCT00493467
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Lymphoma
Completed
Phase Ⅱ
NCT00740948
Tolerance and Efficacy of Rituximab in Sjogren's Disease
Sjogren's Disease
Completed
Phase Ⅱ/Ⅲ
NCT00493454
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Lymphoma
Terminated
Phase Ⅱ
NCT00689845
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B...MoreCombination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
Lymphoma
Recruiting
N/A
NCT00477412
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma
Mantle Cell Lymphoma/Lymphoma
Active not recruiting
Phase Ⅰ
NCT00576758
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT00564512
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
Leukemia
Completed
Phase Ⅲ
NCT00501748
Safety and Tolerability of Rituximab in Neuromyelitis Optica
Neuromyelitis Optica
Completed
Phase Ⅰ
NCT00670358
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stag...MoreLenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT00468442
B-Lymphocyte Immunotherapy in Islet Transplantation
Type 1 Diabetes Mellitus
Terminated
Phase Ⅱ
NCT00595335
Trial of Rituximab for Graves' Ophthalmopathy
Thyroid-associated Ophthalmopa...MoreThyroid-associated Ophthalmopathy
Completed
Phase Ⅱ/Ⅲ
NCT00558181
High-dose Methylprednisolone and Rituximab in High Risk B-CLL
Chronic B-Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00648037
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disor...MoreRituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Hodgkin's Disease/Leukemia/Mye...MoreHodgkin's Disease/Leukemia/Myelodysplastic Syndrome/Non-Hodgkin's Lymphoma
Completed
N/A
NCT00443651
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With A...MoreA Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT00436280
Chemotherapy for Patients With Lymphoma
Lymphoma, Large Cell, Diffuse
Completed
Phase Ⅱ
NCT00451178
An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-C...MoreAn Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only
Lymphoma
Completed
Phase Ⅱ
NCT00656084
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
Relapsed or Refractory Mantle ...MoreRelapsed or Refractory Mantle Cell Lymphoma (MCL)
Completed
Phase Ⅱ
NCT00547534
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT00531089
Rituximab in Patients With Relapsed or Refractory TTP-HUS
Thrombotic Thrombocytopenic Pu...MoreThrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome
Recruiting
Phase Ⅱ
NCT00590447
Risk Stratified Sequential Treatment for CD20-positive PTLD
PTLD/Posttransplant Lymphoprol...MorePTLD/Posttransplant Lymphoproliferative Disorder
Active not recruiting
Phase Ⅱ
NCT00691652
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Lymphoma
Terminated
Phase Ⅰ/Ⅱ
NCT00671658
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute...MoreModified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
Leukemia/Acute Lymphoblastic L...MoreLeukemia/Acute Lymphoblastic Leukemia
Completed
Phase Ⅱ
NCT00642655
Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation
Kidney Transplant
Completed
Phase Ⅰ/Ⅱ
NCT00453102
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Margi...MoreYttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
Marginal Zone Lymphoma
Completed
Phase Ⅱ
NCT00628238
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leuke...MoreMulti-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia/C...MoreChronic Lymphocytic Leukemia/CLL/Untreated/Front-line/First-Line/Initial Therapy
Recruiting
Phase Ⅱ
NCT00486759
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide...MoreA Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
B-cell Lymphoma
Terminated
Phase Ⅲ
NCT00424151
Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
Graves' Dysthyroid Ophthalmopa...MoreGraves' Dysthyroid Ophthalmopathy/Thyroid Related Orbitopathy
Completed
Phase Ⅰ/Ⅱ
NCT00599170
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Diffuse, Large B-Cell, Lymphom...MoreDiffuse, Large B-Cell, Lymphoma
Active not recruiting
Phase Ⅱ
NCT00440388
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Fol...MoreSafety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Follicular Lymphoma
Completed
Phase Ⅱ
NCT00712582
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Ris...MoreTherapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅱ
NCT00433537
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
Contiguous Stage II Mantle Cel...MoreContiguous Stage II Mantle Cell Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Stage I Mantle Cell Lymphoma/Stage III Mantle Cell Lymphoma/Stage IV Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT00719472
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-c...MoreA Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Non-Hodgkin's Lymphoma
Completed
Phase Ⅲ
NCT00499018
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peri...MoreDose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma/...MoreDiffuse Large B-Cell Lymphoma/IPI≥2
Active not recruiting
Phase Ⅲ
NCT00619671
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Refractory Myasthenia Gravis
Completed
Phase Ⅰ/Ⅱ
NCT00503425
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Res...MoreA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD and/or Anti-TNF Therapy.
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT00502840
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had...MoreA Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT00602836
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untr...MoreRituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia/Lymphoma
Active not recruiting
Phase Ⅱ
NCT00556699
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Margi...MoreA Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅰ
NCT00715208
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Relapsed Follicular Lymphoma
Completed
Phase Ⅱ
NCT00425802
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients...MoreChemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Leukemia/Lymphoma
Active not recruiting
Phase Ⅱ
NCT00591630
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplan...MoreZevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
Diffuse Large Cell Lymphoma/Ly...MoreDiffuse Large Cell Lymphoma/Lymphoma
Active not recruiting
Phase Ⅱ
NCT00504777
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthrit...MoreA Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT00498316
Cord Blood Expansion on Mesenchymal Stem Cells
Myelodysplastic Syndrome/Leuke...MoreMyelodysplastic Syndrome/Leukemia
Active not recruiting
Phase Ⅰ
NCT00594815
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly ...MoreCombined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Lymphoma
Completed
N/A
NCT00556127
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse...MoreRituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma/...MoreDiffuse Large B-Cell Lymphoma/POOR PROGNOSIS
Completed
Phase Ⅱ
NCT00509379
Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma
Lymphoma/Non-Hodgkin Lymphoma
Completed
Phase Ⅱ
NCT00738829
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
Leukemia, Lymphocytic, Chronic...MoreLeukemia, Lymphocytic, Chronic, B-Cell
Completed
Phase Ⅰ/Ⅱ
NCT00669877
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt'...MoreRituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
Burkitt's Lymphoma/Burkitt'S-l...MoreBurkitt's Lymphoma/Burkitt'S-like Lymphoma
Completed
Phase Ⅱ
NCT00578305
A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Respo...MoreA Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT00656656
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus
Active not recruiting
Phase Ⅱ
NCT00425217
Rituximab in Membranous Nephropathy
Membranous Nephropathy
Completed
Phase Ⅱ/Ⅲ
NCT00656812
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) L...MoreRituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Lymphoma of Mucosa-Associated ...MoreLymphoma of Mucosa-Associated Lymphoid Tissue
Completed
Phase Ⅱ
NCT00424749
Rituxan in Churg Strauss Syndrome With Renal Involvement
Churg-Strauss Syndrome
Terminated
Phase Ⅱ
NCT00771875
Randomized Trial for Mixed Acute Rejection
Graft Rejection
Completed
Phase Ⅱ
NCT00764517
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chron...MoreVorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
Recurrent B-Cell Non-Hodgkin L...MoreRecurrent B-Cell Non-Hodgkin Lymphoma/Recurrent Chronic Lymphocytic Leukemia/Recurrent Indolent Adult Non-Hodgkin Lymphoma/Refractory B-Cell Non-Hodgkin Lymphoma
Active not recruiting
Phase Ⅱ
NCT00769522
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Leukemia
Active not recruiting
Phase Ⅲ
NCT00532129
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia, Chronic
Completed
Phase Ⅱ
NCT00490529
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Lymphoma, Mantle-Cell
Recruiting
Phase Ⅱ
NCT00505895
FM 140 vs FM100 Study in Patients With Multiple Myeloma
Multiple Myeloma
Completed
Phase Ⅱ
NCT00444912
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relaps...MoreThe Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Non-Hodgkin Lymphoma/Hodgkin D...MoreNon-Hodgkin Lymphoma/Hodgkin Disease
Completed
Phase Ⅱ
NCT00748644
Efficacy Study of Two Treatments in the Remission of Vasculitis
Wegener's Granulomatosis,/Micr...MoreWegener's Granulomatosis,/Microscopic Polyangiitis
Completed
Phase Ⅲ
NCT00738374
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymp...MoreA Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia, Chronic
Completed
Phase Ⅱ
NCT00634179
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
Lymphoma, B-Cell/Follicular Ly...MoreLymphoma, B-Cell/Follicular Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00770562
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiop...MoreA Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Pu...MoreIdiopathic Thrombocytopenic Purpura
Completed
Phase Ⅲ
NCT00765245
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse...MoreLenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00736450
Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, St...MoreOblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Contiguous Stage II Adult Diff...MoreContiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma
Terminated
N/A
NCT00584935
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Ocular Cicatricial Pemphigoid
Completed
Phase Ⅰ/Ⅱ
NCT00472225
Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Steroid-Refractory Chronic GVH...MoreSteroid-Refractory Chronic GVHD
Active not recruiting
Phase Ⅱ
NCT00427856
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With R...MoreSafety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Lymphoma, Follicular
Completed
Phase Ⅱ
NCT00759798
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia/L...MoreChronic Lymphocytic Leukemia/Leukemia
Active not recruiting
Phase Ⅱ
NCT00770224
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stag...MoreS0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00545714
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia, Chronic
Active not recruiting
Phase Ⅱ
NCT00427791
Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic ...MoreRituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
Leukemia
Completed
Phase Ⅱ
NCT00427557
Cellular Therapy With Cord Blood Cells
Multiple Myeloma/Leukemia/Lymp...MoreMultiple Myeloma/Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00553943
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protoc...MorePhase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Lymphoma, Non-Hodgkin/Diffuse ...MoreLymphoma, Non-Hodgkin/Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT00772655
Zevalin® First Line in Follicular Lymphoma
Follicular Lymphoma
Active not recruiting
Phase Ⅱ
NCT00446251
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Tr...MoreEffects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
Kidney Failure, Chronic/Diabet...MoreKidney Failure, Chronic/Diabetic Nephropathies/Glomerulonephritis, IGA/Hypertension, Renal
Completed
Phase Ⅱ
NCT00787969
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lympho...MoreRituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00428142
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With ...MoreBortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00720876
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00788606
R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma/B-cell ...MoreNon-Hodgkin's Lymphoma/B-cell Lymphoma
Terminated
Phase Ⅱ
NCT00541034
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic ...MorePentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00655837
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With D...MoreTrial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Lymphoma, Large B-Cell, Diffus...MoreLymphoma, Large B-Cell, Diffuse/Lymphoma, Non-Hodgkin
Completed
Phase Ⅰ
NCT00578565
Rituximab in Rheumatoid Arthritis Lung Disease
Rheumatoid Arthritis/Interstit...MoreRheumatoid Arthritis/Interstitial Pneumonia
Completed
Phase Ⅲ
NCT00651755
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen i...MoreAprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Lymphoma
Completed
N/A
NCT00521014
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Ref...MoreGM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00477815
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transpl...MoreRituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
Multiple Myeloma and Plasma Ce...MoreMultiple Myeloma and Plasma Cell Neoplasm
Active not recruiting
Phase Ⅰ
NCT00637832
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With...MoreRituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT00424502
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Res...MoreA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT00472849
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Le...MoreOxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
Richter's Transformation/Leuke...MoreRichter's Transformation/Leukemia
Completed
Phase Ⅰ/Ⅱ
NCT00525603
CFAR Study in Patients With Chronic Lymphocytic Leukemia
Leukemia/Chronic Lymphocytic L...MoreLeukemia/Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00450385
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemothera...MoreGenes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)
Lymphoma
Terminated
Phase Ⅱ
NCT00462345
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthrit...MoreA Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT00552461
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
Pulmonary Alveolar Proteinosis...MorePulmonary Alveolar Proteinosis/Primary Disease
Recruiting
Phase Ⅱ
NCT00438880
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurr...MoreAgatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Adult Non-Hodgkin Lymphoma/Ext...MoreAdult Non-Hodgkin Lymphoma/Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue/Nodal Marginal Zone Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Small Lymphocytic Lymphoma/Splenic Marginal Zone Lymphoma/Waldenstrom Macroglobulinemia
Completed
Phase Ⅰ/Ⅱ
NCT00476515
Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossm...MoreRituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor
Kidney Insufficiency
Completed
Phase Ⅰ
NCT00551239
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractor...MoreFludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Leukemia/Lymphoma
Active not recruiting
Phase Ⅲ
NCT00504504
Rituximab and ABVD for Hodgkin's Patients
Lymphoma
Completed
Phase Ⅱ
NCT00578591
Rituximab for GVHD
Graft vs Host Disease/Alogenic...MoreGraft vs Host Disease/Alogenic Hematopoietic Transplant
Withdrawn
Phase Ⅱ
NCT00722137
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rit...MoreStudy of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Mantle Cell Lymphoma
Active not recruiting
Phase Ⅲ
NCT00561379
Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituxi...MoreDiffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab
Lymphoma, Large-Cell, Diffuse
Completed
N/A
NCT00536341
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lympho...MoreFludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00468377
Safety and Efficacy Study of Re-treatment With Rituximab (MabThera/Rituxan) in Patients With Active ...MoreSafety and Efficacy Study of Re-treatment With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNFα Therapies
Arthritis, Rheumatoid
Active not recruiting
Phase Ⅲ
NCT00476229
Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
Lymphoma/Leukemia
Completed
N/A
NCT00612612
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocyt...MoreObatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia/Leukemia/Prolymphocytic Leukemia/Refractory Chronic Lymphocytic Leukemia/Stage I Chronic Lymphocytic Leukemia/Stage II Chronic Lymphocytic Leukemia/Stage III Chronic Lymphocytic Leukemia/Stage IV Chronic Lymphocytic Leukemia
Terminated
Phase Ⅰ
NCT00617929
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem C...MoreAntithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Cancer
Terminated
Phase Ⅱ
NCT00701129
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozym...MoreAn Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
Pompe Disease/Glycogen Storage...MorePompe Disease/Glycogen Storage Disease Type II
Completed
Phase Ⅳ
NCT00625729
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients Wi...MoreDonor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Leukemia/Lymphoma
Terminated
Phase Ⅰ/Ⅱ
NCT00455897
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-...MoreCHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin/Lymphoma...MoreLymphoma, Non-Hodgkin/Lymphoma, B-Cell/Lymphoma, Diffuse
Terminated
Phase Ⅱ
NCT00669318
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lym...MorePentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00647049
Freiburg ZNS-NHL Study
Primary Non Hodgkin Lymphoma o...MorePrimary Non Hodgkin Lymphoma of the Central Nervous System
Recruiting
Phase Ⅱ
NCT00740415
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00492050
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Active not recruiting
Phase Ⅱ
NCT00502996
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Art...MoreA Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT00598169
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients ...MoreBortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Lymphoma
Completed
Phase Ⅰ
NCT00732498
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular ...MoreRituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00499343
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Lymphoma
Completed
Phase Ⅱ
NCT00517699
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Lymphoma
Terminated
Phase Ⅱ
NCT00422799
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Active not recruiting
Phase Ⅱ
NCT00426543
Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome
Primary Sjogren's Syndrome/Xer...MorePrimary Sjogren's Syndrome/Xerostomia/Keratoconjunctivitis Sicca/Fatigue
Completed
Phase Ⅱ
NCT00509184
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
Lymphoma, Malignant
Completed
Phase Ⅱ
NCT00662948
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritum...MoreZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
Lymphoma
Suspended
Phase Ⅱ
NCT00697996
Rituximab for Pediatric Renal Transplant Rejection
Kidney Transplantation
Completed
Phase Ⅱ/Ⅲ
NCT00568815
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (...MoreRituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Lymphoma
Completed
Phase Ⅱ
NCT00502853
A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT00520130
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood an...MoreChemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Myelodysplastic Syndrome/Hodgk...MoreMyelodysplastic Syndrome/Hodgkin's Lymphoma/Non-Hodgkin's Disease/Acute Leukemia/Multiple Myeloma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00726700
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With...MorePegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00432653
Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis
Ankylosing Spondylitis
Not yet recruiting
Phase Ⅱ/Ⅲ
NCT00577161
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolen...MoreFludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
Non-Hodgkin's Lymphoma
Terminated
Phase Ⅲ
NCT00517049
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has P...MoreA Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT00577629
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymph...MoreChemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Lymphoma, B-Cell
Active not recruiting
Phase Ⅱ
NCT00567229
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Multiple Myeloma and Plasma Ce...MoreMultiple Myeloma and Plasma Cell Neoplasm
Terminated
Phase Ⅱ
NCT00496340
Phase II Trial of Pentostatin and Targeted Busulfan
Hematologic Malignancies
Completed
Phase Ⅱ
NCT00579592
Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplana...MoreCampath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
Acute Rejection/Renal Transpla...MoreAcute Rejection/Renal Transplantation
Terminated
N/A
NCT00448019
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00784589
Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphig...MoreComparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus
Pemphigus Disease
Active not recruiting
Phase Ⅲ
NCT00543114
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Terminated
Phase Ⅰ
NCT00515554
HD18 for Advanced Stages in Hodgkins Lymphoma
Hodgkins Lymphoma
Active not recruiting
Phase Ⅲ
NCT00509678
Rituxan With or Without Methotrexate in Psoriatic Arthritis
Psoriatic Arthritis
Completed
Phase Ⅰ
NCT00513747
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Ly...MoreEarly or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Leukemia
Active not recruiting
Phase Ⅲ
NCT00771602
Alemtuzumab + Rituximab Consolidation in CLL
Chronic Lymphocytic Leukemia/L...MoreChronic Lymphocytic Leukemia/Leukemia
Terminated
Phase Ⅱ
NCT00500058
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human I...MoreA Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
B Cell Non-Hodgkin's Lymphoma/...MoreB Cell Non-Hodgkin's Lymphoma/Lymphoma, Non-Hodgkin
Completed
Phase Ⅰ
NCT00576433
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Res...MoreA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
Rheumatoid Arthritis
Completed
Phase Ⅳ
NCT00723658
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By T...MoreS0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
Lymphoma
Withdrawn
Phase Ⅱ
NCT00574730
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's ...MoreCHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
Completed
N/A
NCT00601718
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or ...MoreVorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Adult Nasal Type Extranodal NK...MoreAdult Nasal Type Extranodal NK/T-cell Lymphoma/Anaplastic Large Cell Lymphoma/Angioimmunoblastic T-cell Lymphoma/Contiguous Stage II Mantle Cell Lymphoma/Cutaneous B-cell Non-Hodgkin Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Hodgkin Lymphoma/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Mycosis Fungoides/Sezary Syndrome/Recurrent Small Lymphocytic Lymphoma/Splenic Marginal Zone Lymphoma/Stage I Cutaneous T-cell Non-Hodgkin Lymphoma/Stage I Mantle Cell Lymphoma/Stage I Mycosis Fungoides/Sezary Syndrome/Stage II Cutaneous T-cell Non-Hodgkin Lymphoma/Stage II Mycosis Fungoides/Sezary Syndrome/Stage III Cutaneous T-cell Non-Hodgkin Lymphoma/Stage III Mantle Cell Lymphoma/Stage III Mycosis Fungoides/Sezary Syndrome/Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma/Stage IV Mantle Cell Lymphoma/Stage IV Mycosis Fungoides/Sezary Syndrome/Waldenström Macroglobulinemia
Completed
Phase Ⅰ/Ⅱ
NCT00475423
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Idiopathic Thrombocytopenic Pu...MoreIdiopathic Thrombocytopenic Purpura
Completed
Phase Ⅱ
NCT00550342
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Focal Segmental Glomeruloscler...MoreFocal Segmental Glomerulosclerosis (FSGS)
Completed
Phase Ⅱ
NCT00430352
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin'...MoreMAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Non-Hodgkin's Lymphoma
Completed
Phase Ⅳ
NCT00577993
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Lymphoma
Active not recruiting
Phase Ⅲ
NCT00774462
Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
Myositis/Myasthenia Gravis
Completed
Phase Ⅱ
NCT00565331
Rituximab for Prevention of Rejection After Renal Transplantation
Kidney Transplantation
Completed
Phase Ⅱ/Ⅲ
NCT00772668
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage...MoreRituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma
Lymphoma
Terminated
N/A
NCT00784927
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Un...MoreLenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00695409
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, and High-Dose Combination Chemotherapy Followed By Per...MoreYttrium Y 90 Ibritumomab Tiuxetan, Rituximab, and High-Dose Combination Chemotherapy Followed By Peripheral Blood Stem Cell Transplant in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00588094
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B...MoreDose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Lymphoma/B-cell Non-Hodgkin's ...MoreLymphoma/B-cell Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT00529503
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Pa...MoreA Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Lymphoma, Large B-Cell, Diffus...MoreLymphoma, Large B-Cell, Diffuse/Lymphoma, Non-Hodgkin
Terminated
Phase Ⅱ
NCT00788684
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
CD20-Positive Lymphoid Maligna...MoreCD20-Positive Lymphoid Malignancies/Chronic Lymphoid Leukemia/Hematological Malignancies/Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅰ
NCT00689169
Targeted Intensification Utilizing ZBEAM Followed by Autologous Stem Cell Transplantation (ASCT) in ...MoreTargeted Intensification Utilizing ZBEAM Followed by Autologous Stem Cell Transplantation (ASCT) in Patients With High-grade B-Cell Lymphoma
Lymphoma, Large Cell, Diffuse
Completed
Phase Ⅱ
NCT00562965
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Ch...MoreStudy Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Lymphoma, Follicular
Terminated
Phase Ⅲ
NCT00537290
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Synd...MoreA Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
Antiphospholipid Syndrome
Completed
Phase Ⅱ
NCT00473551
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid...MoreAnti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
Leukemia/Lymphoma/Myeloma
Terminated
Phase Ⅰ
NCT00450801
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00724971
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) ...MoreStudy Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Lymphoma, B-Cell
Completed
Phase Ⅰ
NCT00452374
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Leukemia
Completed
Phase Ⅰ/Ⅱ
NCT00582166
Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT00633594
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Mantle Cell Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00346684
Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
Lymphocyte Predominant Hodgkin...MoreLymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
Completed
Phase Ⅱ
NCT00167791
Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant
End Stage Renal Disease
Withdrawn
N/A
NCT00204659
Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in P...MorePhase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma
Primary Gastric Diffuse-Large ...MorePrimary Gastric Diffuse-Large B-Cell Lymphoma
Completed
Phase Ⅱ
NCT00169169
Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma
CD20-Positive Large B-Cell Lym...MoreCD20-Positive Large B-Cell Lymphoma
Terminated
Phase Ⅲ
NCT00238368
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non...MoreFludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
Lymphoma
Completed
Phase Ⅱ
NCT00114738
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Lymphoma, Mantle Cell/Mantle C...MoreLymphoma, Mantle Cell/Mantle Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT00344149
Rituximab as Second Line Treatment for ITP
Immune Thrombocytopenia (ITP)
Completed
Phase Ⅲ
NCT00279305
Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects
Type 1 Diabetes Mellitus
Completed
Phase Ⅱ/Ⅲ
NCT00266227
A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Met...MoreA Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT00100737
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With...MoreComparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin’s Lymphoma (NHL)
Non-Hodgkin Lymphoma
Terminated
Phase Ⅱ
NCT00183976
Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lympho...MorePegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
Non-Hodgkin's Lymphoma/Burkitt...MoreNon-Hodgkin's Lymphoma/Burkitt Lymphoma/Primary Effusion Lymphomas
Terminated
Phase Ⅱ
NCT00243412
A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthr...MoreA Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate
Rheumatoid Arthritis
Completed
Phase Ⅱ
NCT00267865
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
Lymphoma-AIDS-Related/Brain Ne...MoreLymphoma-AIDS-Related/Brain Neoplasm
Recruiting
Phase Ⅱ
NCT00137995
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Lymphoma, Large-Cell, Diffuse
Completed
Phase Ⅲ
NCT00254163
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in ...MoreFludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
B-Cell Chronic Lymphocytic Leu...MoreB-Cell Chronic Lymphocytic Leukemia
Completed
Phase Ⅲ
NCT00074490
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune ...MoreDonor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Lymphoma/Leukemia/Myeloprolife...MoreLymphoma/Leukemia/Myeloproliferative Disorders/Multiple Myleoma/Myelodysplastic Syndrome
Recruiting
Phase Ⅱ
NCT00307125
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
Kidney Transplant/Kidney Trans...MoreKidney Transplant/Kidney Transplant Recipient/Graft Function/Survival/de Novo HLA Antibodies Development
Completed
Phase Ⅱ
NCT00298272
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab i...MoreSafety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Terminated
Phase Ⅱ
NCT00330252
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Chronic Lymphocytic Leukemia
Completed
Phase Ⅰ
NCT00324831
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Th...MoreGM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Lymphoma
Suspended
Phase Ⅲ
NCT00281918
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chr...MoreFludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Leukemia
Completed
Phase Ⅲ
NCT00369681
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III...MoreRituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00250926
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms M...MoreStudy of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Completed
Phase Ⅱ
NCT00299130
A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared t...MoreA Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT00216164
Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Lymphoma, B-Cell
Terminated
Phase Ⅱ
NCT00392834
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Bur...MoreRituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00229619
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Anemia, Aplastic/Red-Cell Apla...MoreAnemia, Aplastic/Red-Cell Aplasia, Pure/Anemia, Diamond-Blackfan
Completed
Phase Ⅱ
NCT00193505
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Gra...MoreIfosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Non-Hodgkins Lymphoma
Completed
Phase Ⅱ
NCT00244855
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
Contiguous Stage II Grade 1 Fo...MoreContiguous Stage II Grade 1 Follicular Lymphoma/Contiguous Stage II Grade 2 Follicular Lymphoma/Contiguous Stage II Marginal Zone Lymphoma/Cutaneous B-cell Non-Hodgkin Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Grade 1 Follicular Lymphoma/Noncontiguous Stage II Grade 2 Follicular Lymphoma/Noncontiguous Stage II Marginal Zone Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Marginal Zone Lymphoma/Splenic Marginal Zone Lymphoma/Stage I Grade 1 Follicular Lymphoma/Stage I Grade 2 Follicular Lymphoma/Stage I Marginal Zone Lymphoma/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Marginal Zone Lymphoma/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Marginal Zone Lymphoma/Waldenstrom Macroglobulinemia
Completed
Phase Ⅱ
NCT00367497
Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggress...MoreSafety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Terminated
Phase Ⅱ
NCT00180895
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
Burkitt Lymphoma
Terminated
Phase Ⅱ
NCT00199004
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemother...MoreTrial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Adult Acute Lymphocytic Leukem...MoreAdult Acute Lymphocytic Leukemia
Completed
Phase Ⅳ
NCT00385125
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Lymphoma, High-Grade
Recruiting
Phase Ⅱ
NCT00136396
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
Graft vs Host Disease
Completed
Phase Ⅰ/Ⅱ
NCT00387023
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Non-Hodgkin's Lymphoma/Lymphom...MoreNon-Hodgkin's Lymphoma/Lymphoma
Completed
N/A
NCT00376961
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating P...MoreS0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00169156
A Phase II Study of Rituximab Combined With CHOP in T-Cell Angio-Immunoblastic Lymphoma
Untreated T-Cell Angioimmunobl...MoreUntreated T-Cell Angioimmunoblastic Lymphoma
Active not recruiting
Phase Ⅱ
NCT00415506
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
Scleritis/Orbital Disease
Completed
Phase Ⅰ/Ⅱ
NCT00350545
A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Ho...MoreA Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
Graft vs Host Disease/Blood an...MoreGraft vs Host Disease/Blood and Marrow Transplant (BMT)
Active not recruiting
N/A
NCT00364819
Initial Study of Rituximab to Treat Primary Biliary Cirrhosis
Primary Biliary Cirrhosis
Completed
Phase Ⅰ/Ⅱ
NCT00198978
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic ...MoreGerman Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Adult Acute Lymphocytic Leukem...MoreAdult Acute Lymphocytic Leukemia
Recruiting
Phase Ⅳ
NCT00142155
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Completed
N/A
NCT00104299
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Vasculitis/Wegener's Granuloma...MoreVasculitis/Wegener's Granulomatosis/Microscopic Polyangiitis
Completed
Phase Ⅱ/Ⅲ
NCT00308087
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Ly...MoreComparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
Lymphoma, Follicular
Terminated
Phase Ⅱ
NCT00182650
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodg...MoreCellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅰ
NCT00209222
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
Lymphoma, Mantle-Cell
Recruiting
Phase Ⅲ
NCT00201682
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphom...MoreEtanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia/S...MoreChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00286325
Rituximab in the Treatment of Patients With Bullous Pemphigoid
Bullous Pemphigoid
Completed
Phase Ⅰ/Ⅱ
NCT00141700
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin's
Terminated
Phase Ⅱ
NCT00294632
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large...MoreLenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00147953
Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients Wi...MoreStudy to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅱ
NCT00140595
ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and A...MoreACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
Diffuse Large-Cell Lymphoma
Completed
Phase Ⅲ
NCT00384150
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Lymphoma, Non-Hodgkin's
Terminated
Phase Ⅲ
NCT00110006
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patie...MorePositron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
Lymphoma
Withdrawn
N/A
NCT00209209
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Mainten...MoreInduction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
Lymphoma, Mantle-Cell
Recruiting
Phase Ⅲ
NCT00244361
Effectiveness of Rituximab in Pediatric OMS Patients.
Opsoclonus-myoclonus Syndrome/...MoreOpsoclonus-myoclonus Syndrome/Opsoclonus/Myoclonus/Ataxia
Completed
Phase Ⅰ/Ⅱ
NCT00337246
Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chro...MoreCombination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Leukemia
Completed
Phase Ⅱ
NCT00140582
Primary Rituximab and Maintenance
Follicular Lymphoma
Active not recruiting
Phase Ⅲ
NCT00416819
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphom...MoreCombination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Brain and Central Nervous Syst...MoreBrain and Central Nervous System Tumors/Lymphoma
Completed
N/A
NCT00301821
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage I...MoreMonoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00280241
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00109967
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Recurrent Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT00210340
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
Lymphoma, B Cell
Withdrawn
Phase Ⅰ
NCT00265928
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymph...MoreBortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Terminated
Phase Ⅱ
NCT00334438
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or R...MoreBortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅰ
NCT00104858
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Dono...MoreFludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia/P...MoreChronic Lymphocytic Leukemia/Prolymphocytic Leukemia/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Stage III Chronic Lymphocytic Leukemia/Stage III Small Lymphocytic Lymphoma/Stage IV Chronic Lymphocytic Leukemia/Stage IV Small Lymphocytic Lymphoma/T-Cell Large Granular Lymphocyte Leukemia
Active not recruiting
Phase Ⅱ
NCT00363636
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NH...MoreA Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
Lymphoma, Non-Hodgkin's
Terminated
Phase Ⅲ
NCT00275054
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0,...MoreRituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
Leukemia
Recruiting
Phase Ⅲ
NCT00290407
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Leukemia, Lymphocytic, Chronic...MoreLeukemia, Lymphocytic, Chronic/Lymphoma, Small Lymphocytic
Terminated
Phase Ⅱ
NCT00169468
Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma
B Cell Lymphoma
Active not recruiting
Phase Ⅱ
NCT00299104
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With A...MoreA Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅲ
NCT00137969
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosu...MoreA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Completed
Phase Ⅱ/Ⅲ
NCT00117156
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin/MALT Lym...MoreLymphoma, Non-Hodgkin/MALT Lymphoma
Completed
Phase Ⅱ
NCT00244985
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's L...MoreRituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00254410
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With...MoreFCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅱ
NCT00120198
Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymp...MorePegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients
Non-Hodgkin's Lymphoma
Terminated
Phase Ⅱ
NCT00238238
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is No...MoreRituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00250861
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-...MoreTrial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Terminated
Phase Ⅱ
NCT00278421
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Recruiting
Phase Ⅲ
NCT00126191
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Burkitt Lymphoma/Non-Hodgkins ...MoreBurkitt Lymphoma/Non-Hodgkins Lymphoma/Atypical Burkitt Lymphoma
Terminated
Phase Ⅱ
NCT00142168
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia
Terminated
Phase Ⅱ
NCT00267826
Immunopharmacological Effects of Rituximab in Atopic Dermatitis
Dermatitis, Atopic
Completed
N/A
NCT00118209
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
Large B Cell Lymphoma
Active not recruiting
Phase Ⅲ
NCT00259805
A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis
Chronic Focal Encephalitis/Ras...MoreChronic Focal Encephalitis/Rasmussen's Encephalitis
Completed
Phase Ⅰ
NCT00309881
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia That D...MoreCombination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia That Did Not Respond to Fludarabine (Closed to Entry as of 10/2006), Chronic Lymphocytic Leukemia With Autoimmune Hemolytic Anemia, or Richter Transformation
Leukemia
Recruiting
Phase Ⅱ
NCT00400478
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation i...MoreA Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13
Diffuse Large B-Cell Lymphoma ...MoreDiffuse Large B-Cell Lymphoma (DLBCL)/Follicular NHL Grade 3b
Completed
Phase Ⅲ
NCT00400764
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade,...MoreA Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
Non-Hodgkin's Lymphoma
Terminated
Phase Ⅰ/Ⅱ
NCT00225212
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma/Diffuse...MoreNon-Hodgkin's Lymphoma/Diffuse Large Cell Lymphoma/Mantle Cell Lymphoma/Transformed Lymphoma/Other Subtypes of B-cell Lymphoma/Lymphoma
Completed
Phase Ⅱ
NCT00379587
Rituximab for Prevention of Chronic GVHD
Hematological Malignancies
Completed
Phase Ⅰ/Ⅱ
NCT00193466
Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocyti...MoreRituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Non-Hodgkins Lymphoma
Completed
Phase Ⅱ
NCT00295932
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refrac...MoreBortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Leukemia/Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00214266
A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcine...MoreA Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
Renal Transplantation
Completed
Phase Ⅱ
NCT00151281
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅱ
NCT00129090
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-H...MoreMega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma (NHL)
Active not recruiting
Phase Ⅲ
NCT00307593
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
Wegener's Granulomatosis/Churg...MoreWegener's Granulomatosis/Churg-Strauss Syndrome/Microscopic Polyangiitis
Completed
N/A
NCT00201721
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymp...MorePentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
B-Chronic Lymphocytic Leukemia
Active not recruiting
Phase Ⅱ
NCT00251277
Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytop...MoreUse of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Pu...MoreThrombotic Thrombocytopenic Purpura
Withdrawn
Phase Ⅰ/Ⅱ
NCT00311129
Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL
Lymphoma, Low-Grade
Completed
Phase Ⅱ
NCT00290498
Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00371904
Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients
Kidney Transplantation
Recruiting
Phase Ⅱ
NCT00317096
FCM Versus R-FCM Followed by R-Maintenance or Observation Only
Lymphoma, Follicular/Lymphoma,...MoreLymphoma, Follicular/Lymphoma, Low-Grade/Lymphoma, Intermediate-Grade
Active not recruiting
Phase Ⅲ
NCT00201877
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hod...MoreVelcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma/Mantle ...MoreNon-Hodgkin's Lymphoma/Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT00310128
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Pat...MoreCombination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
AIDS-related Lymphoma/Adult No...MoreAIDS-related Lymphoma/Adult Non-Hodgkin's Lymphoma/Anaplastic Large Cell Lymphoma
Withdrawn
Phase Ⅱ
NCT00293072
Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
Systemic Lupus Erythematosus/A...MoreSystemic Lupus Erythematosus/ANCA Associated Vasculitis
Completed
Phase Ⅱ
NCT00278408
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B...MoreRituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00372892
Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopenic, Idi...MorePurpura, Thrombocytopenic, Idiopathic
Completed
Phase Ⅱ
NCT00274989
Bendamustine and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Leukemia
Completed
Phase Ⅱ
NCT00372905
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00126243
Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients ...MoreEfficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma
AIDS Related Lymphoma
Terminated
Phase Ⅱ
NCT00216762
Safety Study of Rituximab (Rituxan®) in Chronic Urticaria
Urticaria
Terminated
Phase Ⅰ/Ⅱ
NCT00183989
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
Mantle Cell Lymphoma
Terminated
Phase Ⅱ
NCT00397800
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients...MoreRituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00281983
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant ...MoreFludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
Leukemia/Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00275613
Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Glomerulonephritis, Membranopr...MoreGlomerulonephritis, Membranoproliferative
Completed
Phase Ⅰ
NCT00168740
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C...MoreTreatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Low-Grade or Follicular B-Cell...MoreLow-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Completed
Phase Ⅲ
NCT00101010
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00151320
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00331006
Rituximab to Treat Severe Hemophilia A
Hemophilia A
Completed
Phase Ⅱ
NCT00101829
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
Sjogren's Syndrome
Completed
Phase Ⅰ
NCT00387959
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients...MoreChemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00383994
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transp...MoreImmunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
Lymphoma/Leukemia/Transplantat...MoreLymphoma/Leukemia/Transplantation, Stem Cell/Lymphoid Malignancies/Disorder Related to Transplantation
Active not recruiting
Phase Ⅰ
NCT00143871
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin's
Completed
Phase Ⅱ
NCT00193492
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
Lymphoma, Follicular
Completed
Phase Ⅱ
NCT00193440
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular No...MoreRituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
Completed
Phase Ⅱ
NCT00127569
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherap...MoreRituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
HIV Infections/Giant Lymph Nod...MoreHIV Infections/Giant Lymph Node Hyperplasia
Terminated
Phase Ⅱ
NCT00396812
Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Terminated
Phase Ⅰ/Ⅱ
NCT00244127
Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.
Aggressive Non-Hodgkin's Lymph...MoreAggressive Non-Hodgkin's Lymphoma in the Elderly.
Active not recruiting
Phase Ⅱ
NCT00169208
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgk...MoreFludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
Follicular Lymphoma
Completed
Phase Ⅱ
NCT00290667
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell L...MoreRituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00361621
Ph II CHOP+Velcade in Mediastinal LBCL
Non-Hodgkin's Lymphoma
Terminated
Phase Ⅱ
NCT00261547
Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
Chronic Rejection/Kidney Insuf...MoreChronic Rejection/Kidney Insufficiency
Completed
Phase Ⅰ/Ⅱ
NCT00119392
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in...MoreYttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia/Nodal Marginal Zone B-cell Lymphoma/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Small Lymphocytic Lymphoma/Splenic Marginal Zone Lymphoma/Waldenström Macroglobulinemia
Active not recruiting
Phase Ⅱ
NCT00274924
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Di...MoreRituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00134082
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgki...MoreRituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00250718
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
Non-Hodgkin's Lymphoma/Cancer
Terminated
Phase Ⅱ
NCT00169143
Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma
Untreated CD20-Positive Large ...MoreUntreated CD20-Positive Large B-Cell Lymphoma
Completed
Phase Ⅱ
NCT00355199
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBC...MoreComparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅲ
NCT00255593
Safety and Efficacy Study of Rituximab in Renal Transplantation
Renal Transplantation
Completed
Phase Ⅰ
NCT00282347
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of N...MoreA Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
Lupus Nephritis
Completed
Phase Ⅲ
NCT00290511
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Ly...MoreRituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00169195
Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma
Diffuse Large Cell Lymphoma
Completed
Phase Ⅱ
NCT00136552
Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden
Lymphoma
Completed
Phase Ⅲ
NCT00150111
Rituximab in the Treatment of Graves' Disease
Graves´ Disease/Thyroid Associ...MoreGraves´ Disease/Thyroid Associated Ophthalmopathy
Completed
Phase Ⅰ/Ⅱ
NCT00135499
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-Cell Lymphoma
Lymphoma, Large-Cell, Diffuse
Terminated
Phase Ⅲ
NCT00193479
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non...MoreCombination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
Completed
Phase Ⅱ
NCT00281931
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
Leukemia
Active not recruiting
Phase Ⅱ
NCT00133991
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma ...MoreCombination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00393107
Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab
Follicular Lymphoma
Completed
Phase Ⅱ
NCT00392691
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transpl...MoreMelphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Lymphoma
Completed
Phase Ⅰ
NCT00258206
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple...MoreRituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
Multiple Myeloma and Plasma Ce...MoreMultiple Myeloma and Plasma Cell Neoplasm
Completed
Phase Ⅱ
NCT00161564
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
Idiopathic Thrombocytopenic Pu...MoreIdiopathic Thrombocytopenic Purpura (ITP)
Withdrawn
Phase Ⅱ
NCT00388193
Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma
Acute Lymphoblastic Leukemia/B...MoreAcute Lymphoblastic Leukemia/Burkitt's Lymphoma
Completed
Phase Ⅱ
NCT00366418
Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukaemia ...MoreChronic Lymphocytic Leukaemia Refractory
Completed
Phase Ⅰ
NCT00208975
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-sti...MorePhase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab
Lymphoma
Terminated
Phase Ⅱ
NCT00312845
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅲ
NCT00381004
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00210353
Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphom...MoreRandomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma
Lymphoma, Mucosa-Associated Ly...MoreLymphoma, Mucosa-Associated Lymphoid Tissue
Active not recruiting
Phase Ⅲ
NCT00299182
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00199082
Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burki...MoreTrial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Burkitt's Lymphoma/Burkitt's L...MoreBurkitt's Lymphoma/Burkitt's Leukemia/Mediastinal Neoplasms/Lymphoblastic Lymphoma/Large Cell Anaplastic Lymphoma
Recruiting
Phase Ⅳ
NCT00143065
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymp...MoreFludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lymphoma, Small Lymphocytic/Ly...MoreLymphoma, Small Lymphocytic/Lymphocytic Leukemia, Chronic
Completed
Phase Ⅱ
NCT00269113
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅲ
NCT00140660
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
Diffuse Large Cell Lymphoma
Terminated
Phase Ⅲ
NCT00288067
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Adult Nodular Lymphocyte Predo...MoreAdult Nodular Lymphocyte Predominant Hodgkin Lymphoma/B-cell Chronic Lymphocytic Leukemia/Contiguous Stage II Adult Burkitt Lymphoma/Contiguous Stage II Adult Diffuse Large Cell Lymphoma/Contiguous Stage II Adult Lymphoblastic Lymphoma/Contiguous Stage II Grade 1 Follicular Lymphoma/Contiguous Stage II Grade 2 Follicular Lymphoma/Contiguous Stage II Mantle Cell Lymphoma/Stage II Marginal Zone Lymphoma/Stage II Small Lymphocytic Lymphoma/Extranodal Marginal Zone B-cell Lymphoma/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Adult Burkitt Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Lymphoblastic Lymphoma/Noncontiguous Stage II Grade 1 Follicular Lymphoma/Noncontiguous Stage II Grade 2 Follicular Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Hodgkin Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Splenic Marginal Zone Lymphoma/Stage I Adult Burkitt Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Stage I Adult Hodgkin Lymphoma/Stage I Adult Lymphoblastic Lymphoma/Stage I Chronic Lymphocytic Leukemia/Stage I Grade 1 Follicular Lymphoma/Stage I Grade 2 Follicular Lymphoma/Stage I Small Lymphocytic Lymphoma/Stage II Adult Hodgkin Lymphoma/Stage II Chronic Lymphocytic Leukemia/Stage III Adult Burkitt Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage III Adult Hodgkin Lymphoma/Stage III Adult Lymphoblastic Lymphoma/Stage III Chronic Lymphocytic Leukemia/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Mantle Cell Lymphoma/Stage III Marginal Zone Lymphoma/Stage III Small Lymphocytic Lymphoma/Stage IV Adult Burkitt Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma/Stage IV Adult Hodgkin Lymphoma/Stage IV Adult Lymphoblastic Lymphoma/Stage IV Chronic Lymphocytic Leukemia/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Mantle Cell Lymphoma/Stage IV Marginal Zone Lymphoma/Stage IV Small Lymphocytic Lymphoma/Waldenström Macroglobulinemia
Terminated
Phase Ⅰ/Ⅱ
NCT00381810
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosu...MoreA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Terminated
Phase Ⅱ/Ⅲ
NCT00261612
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Active not recruiting
Phase Ⅱ
NCT00259974
RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monocl...MoreRIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Polyneuropathy
Completed
Phase Ⅲ
NCT00413959
VELCADE®,Rituximab,Cyclophosphamide and Decadron (VRCD Regimen)
Lymphoma, Non-Hodgkin/Lymphoma...MoreLymphoma, Non-Hodgkin/Lymphoma, B-Cell
Terminated
Phase Ⅱ
NCT00335140
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymp...MoreRituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Lymphoma
Suspended
Phase Ⅱ
NCT00324467
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
Lymphoma, Non-Hodgkin/Advanced...MoreLymphoma, Non-Hodgkin/Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅱ
NCT00379431
A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab
Early and Severe Systemic Scle...MoreEarly and Severe Systemic Sclerosis
Active not recruiting
Phase Ⅱ
NCT00343447
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphoc...MoreCyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
Leukemia
Withdrawn
Phase Ⅱ
NCT00242996
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who...MoreRituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00278161
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's L...MoreRituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00404157
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously ...MoreA Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
Lupus Nephritis
Withdrawn
Phase Ⅲ
NCT00369707
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅱ
NCT00221325
A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain...MoreA Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma
Central Nervous System Lymphom...MoreCentral Nervous System Lymphoma/Intraocular Lymphoma
Completed
Phase Ⅰ
NCT00230035
Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)
Systemic Lupus Erythematosus
Withdrawn
Phase Ⅱ
NCT00248534
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-...MoreRituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00147966
Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)
Rheumatoid Arthritis
Completed
Phase Ⅱ
NCT00115700
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
Follicular Lymphoma
Active not recruiting
Phase Ⅲ
NCT00280878
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
Non-Hodgkin's Lymphoma (CD20+)
Completed
Phase Ⅱ
NCT00785330
Allo-hNHL (FluBuCy)
Non-Hodgkin's Lymphoma
Active not recruiting
Phase Ⅱ
NCT00121199
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cel...MoreCombination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
Contiguous Stage II Adult Diff...MoreContiguous Stage II Adult Diffuse Large Cell Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Stage III Adult Diffuse Large Cell Lymphoma/Stage IV Adult Diffuse Large Cell Lymphoma
Completed
Phase Ⅱ
NCT00293475
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary...MoreMethotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Central Nervous System Lymphom...MoreCentral Nervous System Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Lymphoma, Non-Hodgkin/Lymphoma...MoreLymphoma, Non-Hodgkin/Lymphomas: Non-Hodgkin/Lymphomas: Non-Hodgkin Cutaneous Lymphoma/Lymphomas: Non-Hodgkin Diffuse Large B-Cell/Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell/Lymphomas: Non-Hodgkin Mantle Cell/Lymphomas: Non-Hodgkin Marginal Zone/Lymphomas: Non-Hodgkin Peripheral T-Cell/Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
Completed
N/A
NCT00333008
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large...MoreA Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
Diffuse Large B Cell Lymphoma/...MoreDiffuse Large B Cell Lymphoma/Lymphoma, Non-Hodgkin
Recruiting
Phase Ⅱ
NCT00142116
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemi...MoreWaldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Completed
Phase Ⅱ
NCT00285389
Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years
Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT00107380
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients W...MoreS0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00282308
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid ...MoreA Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
Rheumatoid Arthritis
Completed
Phase Ⅱ
NCT00261118
Rituximab in Active Ulcerative Colitis
Ulcerative Colitis
Completed
Phase Ⅱ/Ⅲ
NCT00412594
2CDA With Rituximab in Hairy Cell Leukemia
Leukemia
Recruiting
Phase Ⅱ
NCT00202930
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
Neuroblastoma/Opsoclonus-Myocl...MoreNeuroblastoma/Opsoclonus-Myoclonus
Recruiting
Phase Ⅱ
NCT00210379
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
Lymphoma, B Cell
Completed
Phase Ⅱ
NCT00119730
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Mantle Cell Lymphoma
Completed
Phase Ⅱ
NCT00147121
Rituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymp...MoreRituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203)
Lymphoma, B-Cell
Active not recruiting
Phase Ⅱ/Ⅲ
NCT00373594
Therapy for Chronic Cold Agglutinin Disease
Cold Agglutinin Disease
Completed
Phase Ⅱ
NCT00410982
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Maligna...MoreGemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Leukemia/Lymphoma/Myeloma
Completed
Phase Ⅰ
NCT00347971
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Completed
Phase Ⅰ
NCT00106184
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyos...MoreRituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Myositis/Dermatomyositis/Polym...MoreMyositis/Dermatomyositis/Polymyositis/Juvenile Dermatomyositis
Completed
Phase Ⅱ
NCT00384553
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Ly...MoreRisk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
Non-Hodgkin's Lymphoma
Recruiting
Phase Ⅰ/Ⅱ
NCT00389818
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell...MoreCombination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00180882
LMBA02 Protocol for Patients With a Burkitt Lymphoma
Burkitt Lymphoma
Recruiting
Phase Ⅲ
NCT00144807
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lympho...MoreACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
Diffuse Large Cell Lymphoma
Completed
Phase Ⅱ
NCT00299494
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subje...MoreStudy Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
B-Cell Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00327678
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
Leukemia, Lymphocytic
Recruiting
Phase Ⅲ
NCT00363350
Rituximab Treatment in Sjogren's Syndrome
Sjogren's Syndrome
Completed
Phase Ⅰ/Ⅱ
NCT00066469
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With L...MoreCyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
Lymphoproliferative Disorder
Active not recruiting
Phase Ⅱ
NCT00053092
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00098488
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapse...More17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia/Refractory Chronic Lymphocytic Leukemia
Terminated
Phase Ⅰ
NCT00039195
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplan...MoreChemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00096044
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymp...MoreLenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Leukemia
Active not recruiting
Phase Ⅱ
NCT00003397
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy i...MorePeripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00045877
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Pre...MoreProleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
Lymphoma, Non-Hodgkin
Completed
Phase Ⅱ/Ⅲ
NCT00003605
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin...MoreRituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Lymphoma
Withdrawn
Phase Ⅱ
NCT00005652
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
Purpura, Thrombocytopenic, Idi...MorePurpura, Thrombocytopenic, Idiopathic
Completed
Phase Ⅱ
NCT00058422
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating O...MoreRituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00069966
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-H...MorePixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00070447
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiux...MoreRituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00072592
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis W...MoreAn Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
Wegener's Granulomatosis
Completed
Phase Ⅰ
NCT00074438
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅱ
NCT00049413
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lym...MoreCombination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00020800
Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia
Lymphoma
Completed
Phase Ⅱ
NCT00005631
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell L...MoreRituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00052923
Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressiv...MoreStem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00086944
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory ...MoreOblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Recurrent Adult Diffuse Large ...MoreRecurrent Adult Diffuse Large Cell Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma
Completed
Phase Ⅰ/Ⅱ
NCT00006436
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Lymphoma, AIDS-related/Lymphom...MoreLymphoma, AIDS-related/Lymphoma, Large B-Cell, Diffuse
Recruiting
Phase Ⅱ
NCT00055640
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00090038
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Ho...MoreEffect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Completed
Phase Ⅳ
NCT00036491
Anti-CD20 in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Completed
Phase Ⅰ/Ⅱ
NCT00063817
Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
Kidney Failure/Bone Marrow Tra...MoreKidney Failure/Bone Marrow Transplantation/Kidney Transplantation/Kidney Failure, Chronic
Completed
Phase Ⅰ
NCT00086775
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Re...MoreFludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
Leukemia
Completed
Phase Ⅱ
NCT00086203
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00093769
Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00003150
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With...MoreCombination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00039130
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Le...MoreRituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00005601
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00020943
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantl...MoreChemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00085696
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphom...MoreVELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
B-Cell Lymphoma/Follicular Lym...MoreB-Cell Lymphoma/Follicular Lymphoma/Marginal Lymphoma
Completed
Phase Ⅱ
NCT00005959
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade N...MoreCombination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00050245
Rituximab to Treat Neuropathy With Anti-MAG Antibodies
Polyneuropathies
Completed
Phase Ⅱ
NCT00052936
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lym...MoreCombination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅲ
NCT00070018
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Ritu...MoreS0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00058227
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disord...MoreAlvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia/Contiguous Stage II Grade 1 Follicular Lymphoma/Contiguous Stage II Grade 2 Follicular Lymphoma/Contiguous Stage II Mantle Cell Lymphoma/Contiguous Stage II Marginal Zone Lymphoma/Contiguous Stage II Small Lymphocytic Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Grade 1 Follicular Lymphoma/Noncontiguous Stage II Grade 2 Follicular Lymphoma/Noncontiguous Stage II Mantle Cell Lymphoma/Noncontiguous Stage II Marginal Zone Lymphoma/Noncontiguous Stage II Small Lymphocytic Lymphoma/Progressive Hairy Cell Leukemia, Initial Treatment/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Refractory Hairy Cell Leukemia/Splenic Marginal Zone Lymphoma/Stage I Chronic Lymphocytic Leukemia/Stage I Grade 1 Follicular Lymphoma/Stage I Grade 2 Follicular Lymphoma/Stage I Mantle Cell Lymphoma/Stage I Marginal Zone Lymphoma/Stage I Small Lymphocytic Lymphoma/Stage II Chronic Lymphocytic Leukemia/Stage III Chronic Lymphocytic Leukemia/Stage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Mantle Cell Lymphoma/Stage III Marginal Zone Lymphoma/Stage III Small Lymphocytic Lymphoma/Stage IV Chronic Lymphocytic Leukemia/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Mantle Cell Lymphoma/Stage IV Marginal Zone Lymphoma/Stage IV Small Lymphocytic Lymphoma/Untreated Hairy Cell Leukemia/Waldenström Macroglobulinemia
Completed
Phase Ⅰ
NCT00088530
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
Lymphoma, Non-Hodgkin
Completed
Phase Ⅲ
NCT00029107
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
Hepatitis C/Vasculitis
Completed
Phase Ⅱ
NCT00098774
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphom...MoreRituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00070083
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patien...MoreOblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Lymphoma
Completed
Phase Ⅰ
NCT00040950
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory...MoreBiological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅰ
NCT00097188
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis
Completed
Phase Ⅱ
NCT00060671
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
Lymphoma, Follicular/Lymphoma,...MoreLymphoma, Follicular/Lymphoma, Mixed-Cell, Follicular/Lymphoma, Small Cleaved-Cell, Follicular/Lymphoma, Low-Grade
Terminated
Phase Ⅲ
NCT00007865
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgki...MoreCombination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00003663
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's...MoreRituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Lymphoma
Withdrawn
Phase Ⅱ
NCT00057811
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed...MoreRituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Childhood Burkitt Lymphoma/Chi...MoreChildhood Burkitt Lymphoma/Childhood Diffuse Large Cell Lymphoma/Childhood Immunoblastic Large Cell Lymphoma/Stage I Childhood Large Cell Lymphoma/Stage I Childhood Small Noncleaved Cell Lymphoma/Stage II Childhood Large Cell Lymphoma/Stage II Childhood Small Noncleaved Cell Lymphoma/Stage III Childhood Large Cell Lymphoma/Stage III Childhood Small Noncleaved Cell Lymphoma/Stage IV Childhood Large Cell Lymphoma/Stage IV Childhood Small Noncleaved Cell Lymphoma/Untreated Childhood Acute Lymphoblastic Leukemia
Completed
Phase Ⅱ
NCT00074282
Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Rela...MorePentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Leukemia
Recruiting
Phase Ⅱ
NCT00087529
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple...MoreA Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
Multiple Sclerosis
Completed
Phase Ⅱ/Ⅲ
NCT00031902
Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅰ
NCT00026351
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymp...MorePentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00004112
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hod...MoreCombination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00004039
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or St...MoreCombination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Lymphoma
Withdrawn
Phase Ⅱ
NCT00053027
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00005589
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Trea...MoreCombination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00073957
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Dif...MoreYttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT00098670
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leu...MoreB-cell Chronic Lymphocytic Leukemia/Stage I Chronic Lymphocytic Leukemia/Stage II Chronic Lymphocytic Leukemia/Stage III Chronic Lymphocytic Leukemia/Stage IV Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00072007
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobiliza...MoreCladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
Leukemia
Completed
Phase Ⅱ
NCT00058461
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-H...MoreCombination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphob...MoreB-cell Childhood Acute Lymphoblastic Leukemia/Childhood Burkitt Lymphoma/Childhood Diffuse Large Cell Lymphoma/Childhood Immunoblastic Large Cell Lymphoma/L3 Childhood Acute Lymphoblastic Leukemia/Recurrent Childhood Acute Lymphoblastic Leukemia/Recurrent Childhood Large Cell Lymphoma/Recurrent Childhood Lymphoblastic Lymphoma/Recurrent Childhood Small Noncleaved Cell Lymphoma
Terminated
Phase Ⅱ
NCT00071396
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disor...MoreCampath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00064116
Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00003554
Rituximab in Treating Patients With Multiple Myeloma
Multiple Myeloma and Plasma Ce...MoreMultiple Myeloma and Plasma Cell Neoplasm
Completed
Phase Ⅱ
NCT00006721
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diag...MoreS0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅲ
NCT00038844
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
Lymphoma/Leukemia
Completed
N/A
NCT00003204
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage...MoreCombination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
Stage III Grade 1 Follicular L...MoreStage III Grade 1 Follicular Lymphoma/Stage III Grade 2 Follicular Lymphoma/Stage III Grade 3 Follicular Lymphoma/Stage III Small Lymphocytic Lymphoma/Stage IV Grade 1 Follicular Lymphoma/Stage IV Grade 2 Follicular Lymphoma/Stage IV Grade 3 Follicular Lymphoma/Stage IV Small Lymphocytic Lymphoma
Completed
Phase Ⅲ
NCT00006669
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non...MoreRituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00045864
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lym...MoreProleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
Lymphoma, Non-Hodgkin
Completed
Phase Ⅱ
NCT00048737
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
Lymphoma/Leukemia
Completed
Phase Ⅰ/Ⅱ
NCT00057343
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Terminated
Phase Ⅲ
NCT00060684
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
Lymphoma, Low-Grade/Lymphoma, ...MoreLymphoma, Low-Grade/Lymphoma, Small Lymphocytic/Lymphoma, Mixed-Cell, Follicular/Lymphoma, Small Cleaved-Cell, Follicular
Completed
Phase Ⅰ
NCT00003595
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previ...MoreCombination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00060346
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macro...MoreRituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
Lymphoma
Terminated
Phase Ⅱ
NCT00096460
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymp...MoreAutologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
Recurrent Grade 1 Follicular L...MoreRecurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Follicular Lymphoma
Terminated
Phase Ⅱ/Ⅲ
NCT00004179
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's ...MoreCombination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅲ
NCT00090051
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Chronic Lymphocytic Leukemia
Completed
Phase Ⅲ
NCT00003658
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia ...MorePentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00006708
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refra...MoreS0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
Terminated
Phase Ⅲ
NCT00057447
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Non-Hodgkin's Lymphoma
Terminated
Phase Ⅰ/Ⅱ
NCT00091897
Rituximab to Treat Stiff Person Syndrome
Stiff Person Syndrome
Completed
Phase Ⅱ
NCT00072514
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previ...MoreGemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Adult Nasal Type Extranodal NK...MoreAdult Nasal Type Extranodal NK/T-cell Lymphoma/Anaplastic Large Cell Lymphoma/Angioimmunoblastic T-cell Lymphoma/Cutaneous B-cell Non-Hodgkin Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Hepatosplenic T-cell Lymphoma/Intraocular Lymphoma/Nodal Marginal Zone B-cell Lymphoma/Noncutaneous Extranodal Lymphoma/Peripheral T-cell Lymphoma/Recurrent Adult Burkitt Lymphoma/Recurrent Adult Diffuse Large Cell Lymphoma/Recurrent Adult Diffuse Mixed Cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Adult Grade III Lymphomatoid Granulomatosis/Recurrent Adult Hodgkin Lymphoma/Recurrent Adult Immunoblastic Large Cell Lymphoma/Recurrent Adult Lymphoblastic Lymphoma/Recurrent Adult T-cell Leukemia/Lymphoma/Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Grade 3 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Mycosis Fungoides/Sezary Syndrome/Recurrent Small Lymphocytic Lymphoma/Small Intestine Lymphoma/Splenic Marginal Zone Lymphoma/Testicular Lymphoma/Waldenstrom Macroglobulinemia
Completed
Phase Ⅱ
NCT00062296
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymph...MoreEpirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00058292
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Periphera...MoreRadiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅰ
NCT00028665
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recu...MoreCyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00087425
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lympho...MoreBryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Leukemia/Lymphoma
Completed
Phase Ⅱ
NCT00028717
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With N...MoreCombination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅲ
NCT00003248
Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymph...MoreFludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia
Leukemia
Completed
Phase Ⅱ
NCT00003820
Rituximab in Treating Patients With Hodgkin's Lymphoma
Lymphoma/Hodgkin Lymphoma (Cat...MoreLymphoma/Hodgkin Lymphoma (Category)
Completed
Phase Ⅱ
NCT00049036
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, S...MoreCombination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
AIDS-related Diffuse Large Cel...MoreAIDS-related Diffuse Large Cell Lymphoma/AIDS-related Immunoblastic Large Cell Lymphoma/AIDS-related Peripheral/Systemic Lymphoma/AIDS-related Small Noncleaved Cell Lymphoma
Completed
Phase Ⅱ
NCT00007852
Rituximab and Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantati...MoreRituximab and Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00003659
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leuke...MoreFludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
Leukemia
Completed
Phase Ⅱ
NCT00068315
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractor...MoreBortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Extranodal Marginal Zone B-cel...MoreExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Hematopoietic/Lymphoid Cancer/Nodal Marginal Zone B-cell Lymphoma/Recurrent Adult Diffuse Small Cleaved Cell Lymphoma/Recurrent Grade 1 Follicular Lymphoma/Recurrent Grade 2 Follicular Lymphoma/Recurrent Mantle Cell Lymphoma/Recurrent Marginal Zone Lymphoma/Recurrent Small Lymphocytic Lymphoma/Refractory Chronic Lymphocytic Leukemia/Splenic Marginal Zone Lymphoma/Waldenström Macroglobulinemia
Completed
Phase Ⅰ
NCT00004031
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemo...MoreSWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00041132
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00003963
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma...MoreChemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Lymphoma
Completed
Phase Ⅱ
NCT00068250
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Prima...MoreCombination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Brain and Central Nervous Syst...MoreBrain and Central Nervous System Tumors/Lymphoma
Active not recruiting
Phase Ⅰ/Ⅱ
NCT00038623
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Ma...MoreStudy Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Completed
Phase Ⅱ
NCT00012051
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Trea...MoreChemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅲ
NCT00032019
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lym...MoreCombination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Completed
Phase Ⅱ
NCT00092222
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Corr...MoreVirotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
Lymphoproliferative Disorder/H...MoreLymphoproliferative Disorder/HHV-8/Malignancy/HIV
Recruiting
Phase Ⅱ
NCT00005089
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage ...MoreS0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Lymphoma
Active not recruiting
Phase Ⅱ
NCT00088881
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I o...MoreRituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
Contiguous Stage II Adult Diff...MoreContiguous Stage II Adult Diffuse Large Cell Lymphoma/Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue/Nodal Marginal Zone B-cell Lymphoma/Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma/Splenic Marginal Zone Lymphoma/Stage I Adult Diffuse Large Cell Lymphoma/Testicular Lymphoma/Waldenström Macroglobulinemia
Terminated
Phase Ⅱ
NCT00001337
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgki...MoreDose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma ...MoreDiffuse Large B-Cell Lymphoma (DLBCL)/Primary Meidastinal Lymphoma/Burkitt Lymphoma/Anaplastic Large-Cell Lymphoma/Gray Zone Lymphoma
Recruiting
Phase Ⅱ
NCT00001586
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene ...MoreTreatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Chronic Lymphocytic Leukemia
Completed
Phase Ⅱ
NCT00001805
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to...MoreA Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
Breast Neoplasms/Colonic Neopl...MoreBreast Neoplasms/Colonic Neoplasms/Lung Neoplasms/Pancreatic Neoplasms/Stomach Neoplasms
Completed
Phase Ⅱ
NCT00001563
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treate...MoreEPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
AIDS Related Lymphoma
Completed
Phase Ⅱ
NCT02767674
Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell L...MoreTrial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Recruiting
Phase Ⅲ
NCT02757196
Treatment of ITP With Rituximab and / or Accutane
Immune Thrombocytopenia
Not yet recruiting
Phase Ⅱ
NCT02741388
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiv...MoreA Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
B-cell Lymphoma
Not yet recruiting
Phase Ⅰ
NCT02705638
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Immunoglobulin G Subclass 4 Re...MoreImmunoglobulin G Subclass 4 Related Disease
Not yet recruiting
Phase Ⅰ
NCT02749292
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
Anti-Neutrophil Cytoplasmic An...MoreAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Not yet recruiting
Phase Ⅳ
NCT02789397
Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatou...MoreClinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID)
Granulomatous and Lymphocytic ...MoreGranulomatous and Lymphocytic Interstitial Lung Disease
Not yet recruiting
Phase Ⅱ
NCT02693210
A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cycloph...MoreA Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Completed
Phase Ⅱ
NCT02703272
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or ...MoreA Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Not yet recruiting
Phase Ⅲ
NCT02733042
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Ther...MoreA Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Lymphoma/Leukemia, Lymphocytic...MoreLymphoma/Leukemia, Lymphocytic, Chronic, B-Cell
Recruiting
Phase Ⅰ/Ⅱ
NCT02674750
Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR...MoreStudy to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL
Relapsed and/or Refractory Dif...MoreRelapsed and/or Refractory Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅱ
NCT02406742
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibruti...MoreA Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL
Leukemia, Lymphocytic, Chronic...MoreLeukemia, Lymphocytic, Chronic, B-Cell
Recruiting
Phase Ⅰ/Ⅱ
NCT02018861
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110...MoreA Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B-Cell Malignancies
B-Cell Malignancies
Recruiting
Phase Ⅰ
Clinical Trial 信息

更新时间：2016-09-28

NCT号
试验标题
适应症
阶段
状态
NCT02727803
Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)
Leukemia/Lymphoma/Myeloma/Myel...MoreLeukemia/Lymphoma/Myeloma/Myeloproliferative Diseases
Recruiting
Phase Ⅱ
NCT02689986
Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
Cold Agglutinin Disease/Autoim...MoreCold Agglutinin Disease/Autoimmune Hemolytic Anemia
Recruiting
Phase Ⅱ
NCT02692248
Evaluation of Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma N...MoreEvaluation of Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to Autologous Stem Cell Transplantation (ASCT)
Diffuse Large B-Cell Lymphoma
Recruiting
Phase Ⅱ
NCT02446457
Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Lymphoma
Recruiting
Phase Ⅱ
NCT02670616
Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B...MoreStudy of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Epstein-Barr Virus-positive Di...MoreEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Recruiting
Phase Ⅱ
Data from http://clinicaltrials.gov查看更多